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Abstract  
 
 Obesity can have numerous detrimental consequences, namely metabolic 
syndrome, type 2 diabetes, cardiovascular disease, cancer, and Alzheimer’s disease. 
The pathogenesis and physiologic consequences of obesity are unknown, but they are 
often associated with increased inflammation and oxidative stress in both the body and 
in the brain.  One factor that has been implicated in causing inflammation associated 
with a high fat diet is the enzyme NADPH oxidase, or NOX, specifically the subunit 
NOX2.  Two studies were performed in order to assess the effects of a high fat diet in 
combination with a universal NOX2 deficiency and a NOX2 deficiency targeted to 
macrophages.  The results of the first study indicate that the NOX2 knockout (NOX2KO) 
mice on a high fat diet do not experience all the deleterious metabolic and inflammatory 
effects in the body and brain to the same degree as wild-type mice.  This suggests that 
a deficiency in NOX2 does offer protection from some of the deleterious effects of a 
high fat diet.  It was also determined from the first study that NOX2 expression is 
localized to macrophages in the visceral adipose tissue.  In order to target these 
macrophages, a second study was conducted.  For this second study, a mouse model 
was genetically engineered with the intent of inhibiting NOX2 solely within 
macrophages.  Similar to the first study, these macrophage-deficient NOX2 knockout 
(macNOX2KO) mice were placed on a high fat along with the NOX2-flox wild-type (WT-
FL) mice.  The results suggest that the macrophage-deficient NOX2 knockout mice 
were protected from the deleterious effects of a high fat diet. 
  
 viii 
 In summary, the deletion of NOX2 appears to offer a protective benefit against 
the deleterious effects of obesity in the context of a high fat diet.  Specifically, the 
deletion of NOX2 in macrophages also offers this protection with the added benefit of 
targeting the deletion so as to not affect NOX2 functioning in other cells in the body. 
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Chapter 1. Introduction and Literature Review 
1.1 Obesity and Its Consequences  
 Over the past 20 years, there has been a dramatic rise in the incidence of obesity 
in the United States.  According to the CDC, in 2010, every state had a prevalence of 
obesity of at least 20%, and 36 states had a prevalence of 25% or more.  In 
comparison, in 2000, the obesity prevalence range was 10-24%.  More than one-third of 
U.S. adults are obese, and about 17% of children and adolescents are obese, indicating 
that obesity is a condition that affects all ages of people (Ogden, 2014).  One of the 
problematic consequences of obesity is that it is costly.  In 2008 the estimated annual 
medical cost of obesity was $147 billion, and these medical costs were $1,429 higher 
for obese people than for those of normal weight (Finkelstein, 2009).  In addition to the 
United States, obesity has become a prominent issue in other parts of the world as 
evidenced by at least 300 million adults being obese on a global scale (World Health 
Organization, 2000). 
 It is difficult to pinpoint exactly what causes obesity, since there are a multitude of 
factors that contribute to its incidence, including genetic predisposition, diet, and 
reduced exercise.  Determining the various causes of obesity is important, since it has 
been shown to be a risk factor for a multitude of diseases including heart disease, 
stroke, dementia, and cancer, and it is the most important risk factor for the 
development of type 2 diabetes (Chan, 1994).  In recent years, obesity has been 
suggested as being linked to cognitive dysfunction and diseases such as Alzheimer’s 
disease (Olufadi, 2008).  For example, studies have reported that increased adiposity or 
obesity is associated with decreased cognitive performance (Smith, 2011), and 
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regression studies have shown that higher body weight is associated with smaller brain 
volume (Ward, 2005).  Clinical obesity is associated with reductions in focal gray matter 
volume and enlarged white matter, particularly in the frontal lobe (Pannacciulli, 2006).  
There is also evidence that specifically indicates that there is an association between 
obesity and type II diabetes and Alzheimer’s disease, and that individuals who are 
obese are at greater risk for Alzheimer’s disease (Luchsinger, 2009).   
 Alzheimer’s disease (AD) is the most common form of dementia among the 
elderly, and the CDC estimates that as many as 5 million Americans have the disease.  
Alzheimer’s disease usually begins at age 60, and the risk increases with age.  About 
50 percent of those 85 years and older may have the disease.  Although uncommon, 
younger people can get the disease as well.  It has been determined that the 
progression of cognitive decline is associated with neuropathological hallmarks that 
include senile plaques that consist of extracellular amyloid beta (Abeta) and intracellular 
neurofibrillary tangles that are comprised of hyperphosphorylated tau protein (Wilkinson, 
2006).  It has also been suggested that four-hydroxynonenal (HNE), an aldehyde 
product of lipid peroxidation, plays a role in the pathogenesis of neuron degeneration in 
AD, thus indicating that increased oxidative stress is involved in the pathogenesis of AD 
(Markesbery, 1998).  Additional research is needed to fully elucidate the causes of 
cognitive decline in AD.   
1.2 Obesity Versus Adiposopathy 
 Obesity in and of itself is not necessarily deleterious or always implicated in 
contributing to diseases.  Obesity can be thought of as having an abnormal amount of 
body fat, which may or may not bring about deleterious health consequences.  In fact, 
 3 
some obese people are metabolically healthy and do not develop any of the various 
diseases that can result from obesity (Karelis, 2004).  Adiposopathy or “sick fat” 
specifically addresses the characteristics of the adipocytes, indicating pathological, 
dysfunctional changes (Bays, 2005).  Despite gaining weight or even fat, some 
individuals do not exhibit the negative metabolic effects which impact health and are 
indicative of adiposopathy.  This is what distinguishes adiposopathy from obesity, in that 
obesity is simply having an extreme amount of body fat, whereas adiposopathy pertains 
to pathological changes in the fat that have an adverse impact on health.  It is important 
to differentiate the two, because adiposopathy is ultimately what can lead to diseases 
such as diabetes and Alzheimer’s disease (Bays, 2005).  Obesity, a sedentary lifestyle, 
and a genetic predisposition are the factors which will often lead to development of 
adiposopathy (Bays, 2005).   
 An individual can be obese and not have adiposopathy and vice versa.  
Individuals can be obese and not suffer from type 2 diabetes mellitus, hypertension or 
dyslipidemia.  These individuals appear to be protected from the adverse metabolic 
consequences typically associated with obesity (Bays, 2005).  Lipodystrophy is a 
situation in which adiposopathy can occur without obesity.  In lipodystrophy, there is a 
deficiency of adipose tissue, which is also associated with insulin resistance (Ganda, 
2000).  Both of these examples indicate that the amount of adipose tissue is not the 
driving factor in causing detrimental health consequences.  In cases of metabolic 
derangement, that is linked with adipose tissue (obesity and too much adipose tissue or 
lipodystrophy and too little or no adipose tissue), there is an impaired capacity to store 
fat in adipose tissue, and this is what can lead to ectopic fat storage and adiposopathy 
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(Goossens, 2008).  This is truly an endocrine disease in that adipose tissue as an organ 
can lead to hormonal disturbances when it is diseased.  Previously, adipose tissue was 
simply viewed as a fat depot and was not considered to play a crucial role in facilitating 
disease conditions.  Or it was thought that adipose tissue played a minor or secondary 
role in the development of disease, while other organs such as the heart, liver, 
pancreas, etc. were thought of as the key contributors.  Now, adipose tissue is regarded 
as a complex endocrine organ that secretes and responds to hormones and plays a 
complex role in many metabolic pathways (Wells, 2012).   
1.3 Pathological Changes in Adipose Tissue 
 In the context of a high fat diet and obesity, normally functioning adipose tissue is 
triggered to undergo adipogenesis, which is the production of additional adipocytes.  If 
adipogenesis is impaired, then already existing adipocytes will undergo further 
adipocyte hypertrophy which may lead to metabolic disease (Bays, 2008).  If 
hypertrophied adipocytes outgrow their blood supply they can become dysfunctional or 
die.  This leads to an increase in adipose tissue hypoxia, production of chemotactic 
factors, and increased free fatty acid (FFA) fluxes (Sun, 2011).  This results in an 
increase in recruitment of macrophages to the adipose tissue, and the macrophages 
form crown-like structures (CLSs) around the dead adipocytes, which are then 
phagocytosed.  The macrophages also produce pro-inflammatory cytokines, which lead 
to the development of insulin resistance (Cinti, 2012).  Insulin resistance along with the 
other conditions of metabolic syndrome, such as visceral adiposity, hypertension,  
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hyperglycemia, and hypertriglyceridemia, are what can lead to diseases such as 
diabetes, cardiovascular disease, and neurodegenerative diseases such as 
Alzheimer’s.   
 When the adipose tissue becomes overloaded, the excess fat can be stored as 
triacylglycerols in non-adipose tissues such as skeletal muscle, liver, and pancreas 
(Goossens, 2008).  This accumulation of triacylglycerols may lead to insulin resistance.  
This ectopic fat deposition is called lipotoxicity and can also occur in individuals with 
lipodystrophy who have a lack of adipose tissue (Bays, 2008).  In the liver, this 
accumulation of triacylglycerols and fatty acids can lead to higher glucose production, 
elevated very low-density lipoprotein-triacylglycerol output, and lower insulin clearance.  
Decreased glucose uptake and glucose oxidation can occur in the skeletal muscle and 
hyperinsulinemia can ensue in the pancreas (Goossens, 2008). 
 In addition to the deleterious metabolic effects and subsequent diseases of 
expanding, dysfunctional adipose tissue, there can also be detrimental effects on the 
brain.  Diet-induced obesity has the potential to induce higher levels of reactive oxygen 
species in the brain (Freeman, 2013).  This oxidative stress can then lead to cognitive 
impairment.  The major inflammatory cells of the CNS are microglia, and these have 
been shown to play a role in the development of diseases such as Alzheimer’s Disease 
(Griffin, 1989).  Microglia serve a critical phagocytic function in the brain, similar to 
peripheral tissue macrophages (Ransohoff, 2009).  Macrophages in the adipose tissue 
and microglia in the brain are upregulated during obesity.  Additionally, it has been 
shown that high-fat diet induced obesity can result in the recruitment of peripheral 
immune cells to the CNS.   
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These cells display characteristics of microglia/macrophages, indicating a possible 
relationship between adipose tissue and brain inflammation (Buckman, 2014). 
1.4 Inflammation, Oxidative Stress, and NADPH oxidase in the Body and Brain 
 While the molecular link(s) between excess adiposity and inflammation have not 
yet been identified, activation of the proinflammatory enzyme NADPH oxidase 
(nicotinamide adenine dinucleotide phosphate-oxidase or NOX) has been implicated in 
the detrimental effects of diet-induced obesity.  NADPH oxidase is a membrane bound 
enzyme complex that consists of membrane components (gp91phox and p22phox) and 
cytosolic components (p47phox, p67phox, and p40phox) that assemble at the plasma 
membrane to form the active oxidase (Babior, 1991 and DeLeo, 1996).  The catalytic 
subunit of NOX is gp91phox (also known as NOX2).  This enzyme complex has the 
function of generating superoxide and other reactive oxygen species by transferring 
electrons across cell membranes in a process referred to as the ‘respiratory burst’.  
Usually the electron acceptor is oxygen and the product of the electron transfer is 
superoxide (Bedard, 2007).  Reactive oxygen species (ROS) are involved in the killing 
of bacteria, fungi, and other pathogens, making ROS an important component in host 
defense.  But despite this beneficial contribution to host defense, ROS are also involved 
in contributing to host damage through interaction with proteins, lipids, carbohydrates, 
and nucleic acids.  In 1956, the role of ROS in the aging process was discovered 
(Harman, 1956).  Since then, the role of ROS as contributors to cellular damage in the 
process of aging has been accepted (Beckman, 1998).   
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 Under normal circumstances, NOX generation of ROS in the adipose tissue 
occurs in response to insulin (Krieger-Brauer and Kather, 1992; Krieger-Brauer and 
Kather, 1997; Mahadev et al., 2001; Mahadev et al., 2004).  This is a physiologically 
important response, because ROS enhance adipocyte differentiation thus allowing for 
glucose uptake (Krieger-Brauer and Kather, 1995).  But in obese animals, in addition to 
ROS production occurring in response to insulin, it can also occur spontaneously.  
NOX2, specifically, appears to be upregulated in obese rats (Furukawa et al., 2004).  A 
study using obese rats found that generation of ROS promoted generation of factors 
involved in metabolic syndrome including plasminogen activator inhibitor 1 (PAI-1) and 
TNF-alpha (Bedard, 2007).  ROS were also found to decrease generation of 
adiponectin, which is a protein involved in glucose regulation and insulin sensitization 
(Bedard, 2007; Furukawa et al., 2004).  Additionally, if there is prolonged exposure to 
ROS, glucose transporter expression may be decreased and glucose uptake may be 
compromised (Rudich et al., 1998).  A study using rats showed that ROS generated 
from NOX2 contributed to the deterioration of beta-cell function.  This study also 
showed that suppression of NOX2 reverses the glucose-induced dysfunction of 
pancreatic NIT-1 cells (Yuan et al., 2010).  
 In addition to adipocytes, NOX generated ROS have also been recognized in 
microglia, and most recently in astrocytes and neurons (Noh, 2000).  The nervous 
system produces large quantities of ROS due to the fact that the nervous system 
accounts for over 20% of the oxygen consumed by the body.  The nervous system is 
also very sensitive to oxidative stress because of polyunsaturated fatty acid enrichment 
in the membranes (Bedard, 2007).  Studies have suggested that ROS generated by 
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NOX can contribute to a variety of diseases of the CNS.  Specifically, numerous studies 
have indicated that microglia respond to neuropathology due to Alzheimer’s disease by 
secreting molecules which activate NOX, thus leading to the production of ROS 
(Wilkinson, 2006).   
 Not only has it been clearly shown that NOX is involved in the pathogenesis of 
AD, studies have also shown increased NOX activation in AD brains through the 
demonstration of translocation of the cytosolic factors p47-phox and p67-phox to the 
plasma membrane (Shimohama, 2000).  In addition to AD brains, it has also been 
shown that there is higher NOX activity in mild cognitive impairment (MCI) brains, 
indicating that NOX may contribute to the early pathogenesis of AD (Bruce-Keller, 
2010).  One study used transgenic mice overexpressing the Swedish mutation of the 
human amyloid precursor protein as a model for AD that also had a NOX subunit 
deleted, and the results showed that the mice did not develop oxidative stress or 
cognitive deficits (Park, 2008).  In a study using APP x PS1 knockin mice, which are a 
model for A-beta pathogenesis, it was found that NOX activity is significantly higher in 
aged APP x PS1 mice and shares a linear relationship with cognitive impairment 
(Bruce-Keller, 2011).  In addition to Alzheimer’s Disease, the effects of NOX have also 
been implicated in Parkinson’s disease, atherosclerosis, diabetic nephropathy, cancer, 
and others (Lambeth, 2007). 
 Despite there being a multitude of studies and data that indicate the contributions 
of NOX2 in the pathogenesis of inflammation and subsequent development of 
adiposopathy, there has not been a study conducted that specifically investigates the 
effects of NOX2 deletion.  Since it has been clearly shown that NOX2 plays a role in 
 9 
these deleterious processes, it is implied that complete removal or inhibition of NOX2 
would have a protective effect.  Because this has not been tested directly, we set out to 
determine if in fact complete deletion of NOX2 in the context of high-fat diet induced 
obesity would result in attenuation of adiposopathy and brain injury.  To accomplish this 
goal, we utilized a mouse model that has a whole-body deletion of NOX2 (NOX2KO 
mice).    
1.5 Mouse Model of Chronic Granulomatous Disease 
 Chronic granulomatous disease or CGD is a group of recessive hereditary 
diseases in which there is chronic inflammation resulting in the formation of granulomas 
(Curnutte, 1993).  These granulomas are often sterile and can involve skin, lung, liver, 
lymph nodes, spleen, and the lining of the gastrointestinal and genitourinary tract 
(Curnutte, 1993; Gallin, 1993).  Individuals with this disease also have increased 
susceptibility to microbial infections due to a mutation in any of the four subunits of 
NOX, which results in absence of respiratory burst activity.  The microbes that are 
particularly problematic are Staphylococcus aureus, Gram-negative enteric bacilli, 
Aspergillus fumigatus, and other fungi (Curnutte, 1993; Gallin, 1983).  The majority of 
these individuals are males hemizygous for mutations in the X-linked gene for gp91phox 
(Royer-Pokora, 1986). 
 There is a mouse model of chronic granulomatous disease that has a non-
functional allele for the gp91phox, or NOX2, subunit.  This knockout mouse was created 
using targeted homologous recombination in murine embryonic stem cells (Pollock, 
1995).  These mice are the first animal model for this disease, and the model closely  
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resembles patients with CGD since they have absence of respiratory burst activity and 
have increased susceptibility to infection with Aspergillus fumigatus and Staphylococcus 
aureus (Pollock, 1995). 
1.6 The Beneficial, Physiological Role of NOX 
 Although NOX has been shown to be involved in the pathogenesis of cognitive 
decline and other diseases, it should also be noted that NOX plays a role in carrying out 
normal, physiological functions, which include innate immunity, signal transduction, and 
biochemical reactions (Lambeth, 2007).  NOX has also been shown to be a key 
regulator of ROS generation in synaptic plasticity and memory formation (Kishida, 
2007).  Although it may seem counterintuitive that NOX could contribute to both 
necessary physiological functions and harmful pathological processes, it can be 
explained in terms of antagonistic pleiotropy, in which the production of ROS by NOX 
early in life is beneficial but becomes harmful due to overexpression later in life 
(Lambeth, 2007).  This is further exemplified by the fact that the majority of diseases 
that result from increased ROS generation due to NOX are chronic in nature and occur 
later in life (Lambeth, 2007).  The use of drugs that target or inhibit specific NOX 
enzymes could potentially be useful in stopping the progression of these diseases that 
occur later in life due to an overabundance of NOX expression (Wilkinson, 2006 
Lambeth, 2007). 
 Because of the beneficial, physiologic roles of NOX, it is necessary to limit the 
NOX2 deletion to those cells in which NOX2 appears to exhibit the greatest contribution 
to adiposopathy.   
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But first it must be determined that NOX2 deletion does indeed result in a protective 
effect.  Once that is determined, then the mechanism by which to target the necessary 
cells will be utilized. 
1.7 Cre-Lox NOX2 Knockout Mouse Model 
 As alluded to previously, knockout mouse models are produced through 
homologous recombination.  This process involves altering a DNA sequence and then 
inserting it into embryonic stem cells to make the gene non-functional.  These 
embryonic stem cells are then injected into host blastocysts eventually resulting in 
targeted mutant mice.  The knockout model is advantageous, because the deletion is 
targeted, not random, and the impact on other genes would likely be minimal.  The 
problem is that, while this whole-body deletion targets NOX2, the deletion occurs 
systemically, thus affecting cells in which NOX2 plays an important, beneficial role.  It 
will be helpful to limit the deletion of NOX2 to a specific cell in order to better elucidate 
its role in high-fat diet-induced adiposopathy.  The Cre-lox system is advantageous in 
that respect, because cell-specific knockouts can be created.  This is done by placing 
loxP sites around the cybb gene and then using a Cre recombinase under the control of 
a LysM promoter, which will result in excision of the cybb gene only in LysM positive 
cells, which are those of the monocytic origin. 
1.8 The Role of NOX2 in Macrophages 
 Resident macrophages are necessary in order to maintain adipose tissue 
homeostasis, but in the scenario of obese adipose tissue, the macrophages can take on 
a pathologic inflammatory nature, which can subsequently contribute to pathologies 
such as insulin resistance.  These different populations of adipose tissue macrophages 
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have been referred to as M1 and M2, with M1 referring to the inflammatory 
macrophages and M2 referring to the resident macrophages (Hill et al., 2014).  In 
addition to these different populations, it has been shown that total macrophage number 
increases in the context of obesity.  Macrophages may initiate inflammatory pathways in 
the adipose tissues (Weisberg, 2003) and can disrupt function by inducing insulin 
resistance, inducing adipocyte chemokine and cytokine production, or by impacting 
adipose tissue expansion capacity during obesity (Hill et al., 2014). 
 Microglia share many characteristics with peripheral tissue macrophages 
(Ransohoff and Perry, 2009).  Microglia in the central nervous system play a critical role 
in the pathology of conditions such as Alzheimer’s Disease (Griffin et al., 1989).  In the 
context of high-fat diet-induced obesity, there is an increased activation of microglia 
(Thaler et al., 2012; Yi et al., 2012).  There is also an increased recruitment of bone 
marrow-derived monocytes into the central nervous system (Buckman, 2013), thus 
indicating that infiltration of macrophages into the visceral adipose tissue may induce 
systemic effects leading to increased macrophages in the brain.  
 NOX2 can be found in a wide assortment of cells, but the majority of NOX2 
expression occurs in phagocytes, namely macrophages (Bedard, 2007).  In reference to 
NOX2’s expression in adipose tissue specifically, it has been shown that expression 
occurs in both rodents and humans (Sakurai et al., 2009; Catalan et al., 2011).  Unlike 
NOX4, NOX2 expression in adipocytes is quite low (Han et al., 2012), suggesting that 
NOX2 expression may occur in the macrophage cells in adipose tissue.  In light of this 
evidence, it will be advantageous to target myeloid lineage cells, which includes 
monocytes, macrophages, and microglia, when designing a cre-lox mouse model. 
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1.9 Objectives 
 The first objective of this project was designed to elucidate the effects of NOX2 
deletion on both the body and the brain in the context of a high-fat diet.  This was done 
in order to examine if deletion of NOX2 would provide protection against metabolic and 
brain impairments.  The second objective was to determine where the majority of NOX2 
expression occurs in the visceral adipose tissue.  The third objective was to target 
NOX2 deletion to macrophages.  By doing this, the physiological functioning of NOX2 in 
other cells can be preserved.  This will help pave the way for investigating potential 
ways of blocking NOX2 in macrophages, which will aid in the prevention of the 
development of adiposopathy.   
Specific Aims 
1.  Utilized a mouse model with a global knockout of NOX2 and evaluated these mice 
on a high fat diet along with the wild-type counterparts.  Various parameters were 
measured in order to assess the degree of inflammation in the adipose tissue and the 
brain.  This is necessary in order to validate that NOX2 deletion does indeed offer 
protection in the face of high-fat diet induced obesity.  Our hypothesis is that NOX2 
knockout (NOX2KO) mice will be protected from the high-fat diet as compared to wild-
type mice. 
2.  Determined through immunohistochemistry, where the majority of NOX2 expression 
occurs in the visceral adipose tissue. 
3.  Designed a cre-lox NOX2 knockout mouse model.  This is necessary in order to 
target the NOX2 deletion to macrophages specifically. 
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4.  Placed these genetically engineered macrophage-deficient NOX2 knockout 
(macNOX2KO) mice on a high fat diet along with their NOX2-flox wild-type (WT-FL) 
counterparts.  Various parameters were measured in order to assess the degree of 
inflammation in the adipose tissue and the brain.  This is necessary in order to elucidate 
the protective effects that occur when NOX2 deletion is targeted to macrophages.  Our 
hypothesis is that macrophage-specific NOX2 deletion plays a key role against 
protection of adiposopathy and cognitive impairment while preserving the beneficial 
roles of NOX. 
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Chapter 2. NOX2 Deficiency Attenuates Markers of Adiposopathy and 
Brain Injury Induced by High-Fat Diet 
 
“This chapter, NOX2 Deficiency Attenuates Markers of Adiposopathy and Brain Injury 
Induced by High-Fat Diet, previously appeared as Jennifer K. Pepping, Linnea R. 
Freeman, Sunita Gupta, Jeffrey N. Keller and Annadora J. Bruce-Keller, NOX2 
deficiency attenuates markers of adiposopathy and brain injury induced by high-fat diet, 
American Journal of Physiology Endocrinology and Metabolism, 304: E392-E404, 2013.  
It is reprinted by permission of the American Physiological Society.” 
 
2.1 Introduction 
 Diet-induced obesity may be the primary cause of metabolic syndrome, which is 
associated with dramatically enhanced risk for many diseases, including type 2 
diabetes, cardiovascular disease, stroke, and cancer (Haslam and James, 2005). In 
recent years, diet-induced obesity has also been linked to brain pathology, cognitive 
dysfunction, and Alzheimer's disease (Olufadi and Byrne, 2008). For example, studies 
have reported deficits in learning, memory, and cognitive processing in obese compared 
with nonobese patients (Elias et al., 2003; Elias et al., 2005; Waldstein and Katzel, 
2006), and regression studies have demonstrated that higher body weight is associated 
with smaller brain volume (Ward et al., 2005). Additionally, clinical obesity is associated 
with reductions in focal gray matter volume and enlarged white matter, particularly in the 
frontal lobe (Pannacciulli et al., 2006). While it is not fully understood how obesity 
destabilizes health, obesity is closely associated with a pattern of chronic inflammation 
thought to originate in adipose tissue (Shoelson et al., 2007), resulting in enhanced 
cytokine production, increased acute-phase reactants, and other inflammatory 
mediators (Berg and Sherer, 2005; Chandalia and Abate, 2007; Hotamisligil 2006).  
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Activation of these inflammatory markers correlates tightly with insulin resistance 
(Pickup and Crook, 1998), cardiovascular disease (Rader, 2000), and cognitive 
impairment (Dziedzic, 2006; Trollor et al., 2012). 
 While the molecular link(s) between excess adiposity and inflammation has not 
yet been identified, recent reports have implicated activation of the proinflammatory 
enzyme NADPH oxidase in the detrimental effects of diet-induced obesity. NADPH 
oxidase is a superoxide-producing complex consisting of membrane (gp91phox and 
p22phox) and cytosolic (p47phox, p67phox, and p40phox) components which assemble 
at the plasma membrane to form the active oxidase (Babior, 1991; DeLeo and Quinn, 
1996). NADPH oxidase is expressed in many types of immune cells including 
macrophages, dendritic cells, and neutrophils, as well as in adipocytes, endothelial 
cells, and neurons. With regard to the participation of NADPH oxidase in obesity, 
studies from our laboratory show that NADPH oxidase activity/expression is increased 
in the brains of mice given a high-fat diet (Bruce-Keller et al., 2010), a scenario also 
observed in rats (Zhang et al., 2005). Obesity-associated alterations in both endothelial 
cells (Chinen et al., 2007; Silver et al., 2007) and leukocytes (Patel et al., 2007) have 
been linked to NADPH oxidase. Once activated in the brain, NADPH oxidase is thought 
to trigger inflammatory processes that can contribute to CNS disease (Block, 
2008; Lambeth, 2007; Shimohama, 2000). For example, data from our laboratory and 
others' show the critical role that NADPH oxidase plays in directing brain inflammation, 
particularly in the release of proinflammatory cytokines, including TNFα, IL-6, and IL-1β 
(Clark and Valente, 2004; Robertson et al., 1990; Turchan-Cholewo et al., 2009).   
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Release of all of these cytokines has the potential to underlie neurological impairment 
(Akiyama et al., 2000; Arvin et al., 1996; Lane et al., 1996; Parnet et al., 2002; Tyor et 
al., 1992). 
 Despite the evidence of a role for NADPH oxidase in the adverse effects of 
obesity, the effects of NADPH oxidase subunit deletion have not yet been tested in 
models of diet-induced obesity. To address this issue, this study employed a mouse 
model of chronic granulomatous disease (CGD), an inherited deficiency in NADPH 
oxidase based on deletion of the catalytic gp91phox subunit (also known as NOX2). 
The effects of high-fat diet were compared in wild-type C57Bl/6 (WT) mice and NOX2-
deficient (NOX2KO) mice.  Our hypothesis is deletion of NOX2 will offer significant 
protection from the detrimental neurological and/or physiological consequences of diet-
induced obesity. 
2.2 Materials and Methods 
Animal treatments 
 The Institutional Animal Care and Use Committee at the Pennington Biomedical 
Research Center approved all experimental protocols, which were compliant with NIH 
guidelines on the use of experimental animals. Four-month-old male C57Bl/6 (WT) and 
B6.129S-Cybbtm1Din/J (NOX2KO) mice were purchased from Jackson Laboratories 
(Bar Harbor, ME) and were housed in standard caging with a 12:12-h light-dark cycle 
and ad libitum access to food and water. C57Bl/6 mice were housed in standard 
conventional rooms, whereas NOX2KO mice were housed under sterile conditions to 
accommodate the CGD phenotype, which is characterized by recurrent bacterial and 
fungal infections leading to excessive inflammation (Morgenstern, 1997). Both WT and 
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NOX2KO mice were separated into groups given either a high-fat diet (HFD) or a low-fat 
control diet (CD) for 14 weeks. The HFD was composed of 60% fat (pork lard), and the 
control diet was composed of 10% fat. Both diets were open source, were purchased 
from Research Diets (New Brunswick, NJ; HFD: D12492; CD: D12450B), and were 
provided in pelleted form. Data were compiled from two separate experiments, each 
composed of both WT and NOX2KO mice given CD or HFD, with 9–10 total animals in 
each group. 
 Body weight, food intake, and body composition [measured using a Bruker 
minispec LF90 time domain Nuclear Magnetic Resonance (NMR) analyzer; Bruker 
Optics, Billerica MA] were measured twice per month. Fasting blood glucose was 
measured in tail blood using a glucometer (Ascensia Elite, Bayer, Mishawaka, IN), and 
glucose tolerance was measured using a modified oral glucose tolerance test (OGTT). 
Briefly, mice were fasted for 4 h, baseline glucose was measured, and then mice were 
immediately administered glucose (2 g/kg) via oral gavage. Blood glucose was 
measured at 15, 30, 60, and 120 min, and area under the curve (AUC) was recorded as 
an index of glucose disposal. To measure circulating nonesterified fatty acids (NEFA) in 
the context of hyperglycemia, additional blood samples (∼50 µl) were collected at 0 and 
60 min by lancing the submandibular vein (Fernandez et al., 2010), and NEFA were 
analyzed as described below. All mice were humanely euthanatized via isoflurane 
inhalation and cardiac exsanguination after a brief (6 h) fast, and blood, brain (anterior 
1/3 of cerebral cortex), and visceral (epididymal) and subcutaneous (inguinal) adipose 
tissue depots were collected. 
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Clinical chemistry 
 Whole blood was collected by cardiac exsanguination of anesthetized mice and 
was allowed to clot at 4°C overnight and then centrifuged at 3,000 x g for 30 min. Serum 
was collected and either analyzed immediately or aliquoted and stored at −80°C. Levels 
of total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and NEFA in sera 
were measured colorimetrically using commercially available kits (Wako Chemicals, 
Richmond, VA). Insulin levels were evaluated by ELISA in accordance with the 
manufacturer's assay protocol (Crystal Chem, Downers Grove IL). 
Histological and biochemical analyses of adipose tissue 
 The inguinal and epididymal adipose depots were collected for histological and 
biochemical analyses. For histology, the tissues were immersion-fixed in 10% neutral 
buffered formalin for 2–3 days, after which they were processed for paraffin embedding. 
Sections (5 µm) were then cut, stained with hematoxylin and eosin, and digitized. 
Adipocyte size was measured by an investigator blinded to the experimental grouping in 
×40 microscope fields by counting the total number of adipocytes within predefined area 
grids and then dividing the area by the total number of adipocytes within the grids to 
calculate average adipocyte size. For each sample, three tissue sections were 
analyzed, with three fields counted in each section, for an average of nine fields per 
sample. 
 For Western blot, adipose tissue samples were homogenized in 
radioimmunoprecipitation assay (RIPA) buffer (G biosciences, St. Louis, MO) and then 
cleared by centrifugation at 5,000 x g for 10 min at 4°C. Samples were denatured in 
SDS, and equivalent amounts of protein were electrophoretically separated in 
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polyacrylamide gels and blotted onto nitrocellulose. Blots prepared from adipose tissue 
were processed using anti-Iba-1 (1:500, Wako Chemicals, Richmond, VA), anti-
PPARγ1/2 (1:1,000, Abcam, Cambridge, MA), anti-adiponectin (1:1,000, Abcam), anti-
GADD153/CHOP (1:5,000, Abcam), anti-GRP78 (1:500, Novus Biologicals), and anti-
tubulin (1:1,000, Wako Chemicals). After incubation with primary antibodies, blots were 
washed and exposed to horseradish peroxidase-conjugated secondary antibodies and 
visualized using a chemiluminescence system (Amersham Biosciences, Pittsburgh, 
PA). Blot images were scanned and densitometrically analyzed for quantification. To 
ensure accurate quantification across multiple blots, samples from all groups (HFD and 
CD in both WT and NOX2KO) were included in each individual blot. Data were 
calculated as a ratio of expression over tubulin expression, which was included as an 
internal loading control. Protein expression in HFD mice was then calculated and 
presented as percent expression relative to CD mice of the same genotype. 
 For immunohistochemical analyses of adipose depots, tissue sections were 
processed using anti-Iba-1 (1:100, Wako Chemicals) and anti-NOX2 (1:100, Santa Cruz 
Biotechnology). Sections were incubated with biotinylated or peroxidase-linked 
secondary antibodies and then visualized using diaminobenzidine (for Iba1) or 
NOVAred (for NOX2) as chromagens following the manufacturer's instructions (Vector 
Laboratories, Burlingame, CA). To document nonspecific staining, the primary 
antibodies were omitted from the staining protocol. To visualize the cellular distribution 
of NADPH oxidase subunit expression, sections were first labeled for NOX2 and then 
double-labeled using Iba-1 as a macrophage cell marker. 
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Measures of brain injury by western blot 
 Tissue samples generated from frontal cortices were homogenized and 
processed for Western blot with chemiluminescence, as described in previous reports 
(Bruce-Keller et al., 2011; Pistell et al., 2010). Blots were processed using the following 
primary antisera: anti-claudin-5 (1:400, Abcam), anti-ZO-1 (1:100, Abcam), anti-occludin 
(1:8,000, Abcam), anti-matrix metalloproteinase-2 (MMP2; 1:1,000, Abcam), anti-MMP9 
(1:1,000, Abcam), anti-synapsin 1 (1:10,000, Thermo Fisher Scientific, Pittsburg, PA), 
anti-phospho(Ser553)-synapsin 1 (1:10,000, Abcam), anti-synapse-associated protein-97 
(SAP97; 1:2,500, Abcam), anti-glial fibrillary acidic protein (GFAP; 1:5,000, Abcam); 
anti-Iba-1 (1:500, Wako Chemicals), and anti-tubulin (1:1,000, Wako Chemicals). To 
ensure accurate quantification across multiple blots, samples from all groups were 
included in each individual blot. Data were first calculated as a ratio of expression over 
tubulin expression, which was included as an internal loading control, and then protein 
expression in HFD mice was calculated and presented as percent expression relative to 
CD mice of the same genotype. 
Statistical analyses 
 All data are shown as means ± SE. Body weight and composition data, adipocyte 
size, and all metabolic data were all analyzed with two-way analyses of variance 
(ANOVA) followed by planned Bonferroni posttests to determine the effects of HFD in 
both WT and NOX2KO mice. Additional planned comparisons of WT and NOX2KO 
mice under both CD and HFD conditions were carried out to determine the effects of 
genotype under both diet conditions. Significant effects of diet are indicated with “*” (*p 
< 0.05, **p < 0.01, and ***p < 0.001), while significant effects of genotype are indicated 
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with “#” (#p < 0.05, ##p < 0.01, and ###p < 0.001). Protein expression values generated 
by Western blot (ratios of expression over tubulin) were normalized to percent CD for 
each genotype to reconcile data from multiple blots and were analyzed by two-tailed, 
unpaired t-tests to determine if statistically significant differences existed between HFD 
and CD groups within each genotype.  
2.3 Results 
Effects of HFD on body weight and composition in WT and NOX2KO mice 
 Four-month-old male WT and NOX2KO mice were fed either HFD or CD for 14 
wk as described in Materials and Methods. During that time, body weights progressively 
diverged such that, by the end of the diet exposure period, the weights of the HFD-fed 
mice were significantly higher than CD mice, although all mice gained weight (Fig 2.1-
A). Statistically, ANOVA for genotype X diet revealed a significant main effect of diet on 
body weight (F(1,35) = 82.82, p < 0.0001). The effect of genotype on body weight was 
also significant (F(1,35) = 2.27, p = 0.030), but the interaction was not. Planned 
comparisons of NOX2KO and WT mice revealed that, although there were no significant 
differences between body weights in mice given CD, HFD-fed NOX2KO mice had 
significantly higher weights than the HFD-fed WT mice after 4 and 6 wk of diet 
consumption (Fig 2.1-A). Analysis of food intake during this period did not reveal any 
differences between WT and NOX2KO mice with regard to diet (CD or HFD) ingestion 
(data not shown), indicating that NOX2 is not involved in feeding behavior and that the 
increased body weight in NOX2KO mice was not caused by increased food intake. In 
addition to body weight, total body fat was measured using NMR as described 
in Materials and Methods. Similar to what was observed for body weight, the amount of  
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Figure 2.1:  Effects of high-fat diet (HFD) on body weight and composition in WT and 
NADPH oxidase subunit 2 knockout (NOX2KO) mice. Four-month old male C57Bl/6 
(WT) mice and B6.129S-Cybbtm1Din/J (NOX2KO) mice were placed for 14 weeks on 
HFD or the nutritionally matched low-fat control diet (CD) with 10 mice in each group. 
Significant effects of genotype are indicated with “#” (#p < 0.05, ##p < 0.01, and ###p < 
0.001). Figure 2.1-A: Body weight in WT and NOX2KO mice over time following 
administration of CD or HFD. Significantly (#p < 0.05) higher body weight noted in 
NOX2KO vs. WT mice after 4 and 6 weeks of diet. Figure 2.1-B: Body fat as %total 
body weight in WT and NOX2KO mice over time following administration of CD or HFD. 
Significantly (#p < 0.05, ##p < 0.01, respectively) lower body fat percentage in NOX2KO 
vs. WT mice after 11 and 14 wk of HFD. Figure 2.1-C: Lean body mass as %total body 
weight in WT and NOX2KO mice over time following administration of CD or HFD. 
Significantly (#p < 0.05, ##p < 0.01, respectively) higher lean body percentage in 
NOX2KO vs. WT mice after 11 and 14 weeks of HFD.  
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body fat (expressed as %total body weight) was higher in all mice over the 14-wk 
feeding trial, but mice given HFD had the greatest amounts of body fat (Fig 2.1-B). 
Statistically, ANOVA to measure the effects of genotype and diet on percent body fat 
revealed a significant main effect of diet (F(1,33) = 53.68, p < 0.0001). The effect of 
genotype on body fat was also significant (F(1,33) = 4.41, p = 0.033), with a significant 
interaction between diet and genotype (F(1,33) = 8.63, p = 0.0038). Planned comparisons 
of NOX2KO and WT mice revealed no genotype-based differences in percent body fat 
in mice given CD but did reveal higher body fat in WT compared with NOX2KO mice 
after 11 and 14 wk of HFD (Fig 2.1-B). NMR-based measures of lean body mass 
(expressed as %total body weight) revealed a lower lean body mass percentage in all 
mice over the 14-wk feeding trial, with mice given HFD having the least amount of lean 
body mass by the end of the feeding trial (Fig 2.1-C). Statistically, two-way ANOVA 
revealed a significant main effect of diet on lean body mass (F(1,35) = 52.10, p < 0.0001). 
The effect of genotype on body weight was also significant (F(1,35) = 9.27, p = 0.0038), 
but the interaction was not. Planned comparisons of NOX2KO and WT mice revealed 
no differences in percent lean mass in mice given CD but did reveal more lean mass in 
NOX2KO mice compared with WT mice after 11 and 14 wk of HFD (Fig 2.1-C). 
 After the mice were euthanized, the subcutaneous inguinal and visceral 
epididymal adipose depots were collected for analysis. Comparison of the wet weights 
of the individual fat pads revealed that mice on the HFD had a significantly heavier 
subcutaneous inguinal fat pad. Specifically, ANOVA for the effects of genotype X diet on 
the weight of the inguinal fat pad revealed a significant main effect of diet (F(1,35) = 
78.19, p < 0.0001), but no effect of genotype and no interaction (Fig 2.2-A), whereas  
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Figure 2.2:  Effects of HFD on adipose depot weights in WT and NOX2KO mice.  
Subcutaneous inguinal and visceral epididymal fat pads were collected from WT and 
NOX2KO mice at the end of the 14-week feeding trial and weighed. Data were collected 
from 10 mice in each group except for the NOX2KO/HFD group, which had 9 samples.  
Significant effects of diet are indicated with “*” (*p < 0.05, **p < 0.01, and ***p < 0.001), 
while significant effects of genotype are indicated with “#” (#p < 0.05, ##p < 0.01, and 
###p < 0.001). Figure 2.2-A: Inguinal fat depot weight in WT and NOX2KO mice 
following administration of CD or HFD. Significantly (***p < 0.001) higher weight of 
inguinal fat depot in both WT and NOX2KO mice on HFD vs CD. Figure 2.2-B: 
Epididymal fat depots in WT and NOX2KO mice following administration of CD or HFD. 
Significantly (*p < 0.05) higher weight of epididymal fat depot in WT mice given HFD vs. 
WT mice on CD. Significantly (#p < 0.05) lower weight of epididymal fat depot in 
NOX2KO mice vs. WT mice on HFD. 
 
post hoc tests confirmed that HFD significantly increased the weight of the inguinal fat 
pad in both WT and NOX2KO mice. Planned comparisons of NOX2KO and WT mice 
revealed no differences in the weight of the inguinal adipose depot in mice given CD; 
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likewise, the inguinal adipose depot in HFD-fed WT mice was not statistically different in 
size from the inguinal depot isolated from HFD-fed NOX2KO mice (Fig 2.2-A). Visceral 
adipose was likewise analyzed, and ANOVA for the effects of genotype X diet on the 
weight of the epididymal fat pad showed no main effect of either diet or genotype but 
did reveal a significant interaction (F(1,35) = 10.51, p = 0.0401; (Fig 2.2-B). Post hoc 
tests showed that HFD significantly increased epididymal adipose depot weight in WT 
mice but not in NOX2KO mice, whereas planned comparisons of NOX2KO and WT 
mice revealed that the epididymal adipose depot in HFD-fed NOX2KO mice was 
significantly lower than that isolated from HFD-fed WT mice (Fig 2.2-B). 
Diet-induced adipocyte hypertrophy and inflammation in WT and NOX2KO mice 
 As obesity and metabolic dysfunction are frequently associated with adipocyte 
enlargement or hypertrophy (Bays et al., 2008; Heilbronn et al., 2004), the size of 
individual adipocytes within subcutaneous inguinal and visceral epididymal adipose 
depots was evaluated in tissue sections as described in Materials and Methods. Such 
measurements revealed that HFD-fed mice had significantly larger subcutaneous 
inguinal adipocytes (Fig 2.3-A). Specifically, ANOVA for the effects of genotype and diet 
on inguinal adipocyte size revealed a significant main effect of diet (F(1,33) = 47.79, p < 
0.0001) but no effect of genotype and no interaction. Planned comparisons revealed no 
differences in the size of inguinal adipocytes in CD-fed NOX2KO and CD-fed WT mice 
and likewise showed that both WT and NOX2KO HFD-fed mice had larger 
subcutaneous adipocytes (Fig 2.3-A). With respect to visceral adipocytes, two-way 
ANOVA on the effects of genotype and diet on epididymal adipocyte size revealed a 
significant main effect of diet (F(1,34) = 38.40, p < 0.0001). Although there was no  
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Figure 2.3: Effects of HFD on adipocyte hypertrophy in WT and NOX2KO mice.   
Subcutaneous inguinal and visceral epididymal fat pads were collected from WT and 
NOX2KO mice at the end of the 14-week feeding trial and processed for histological 
analyses of adipocyte size as described in Materials and Methods. Data were collected 
from 10 mice in each group except for the NOX2KO/HFD group, which had 9 samples. 
Significant effects of diet are indicated with “*” (*p < 0.05, **p < 0.01, and ***p < 0.001), 
while significant effects of genotype are indicated with “#” (#p < 0.05, ##p < 0.01, and 
###p < 0.001). Figure 2.3-A: Size of inguinal adipocytes in WT and NOX2KO mice after 
administration of CD or HFD. Significantly (**p < 0.01) larger adipocytes in WT mice on 
HFD vs. WT mice on CD; Significantly (***p < 0.001) larger adipocytes in NOX2KO mice 
on HFD vs. NOX2KO mice on CD. Figure 2.3-B: Size of epididymal adipocytes in WT 
and NOX2KO mice after administration of CD or HFD. Significantly (***p < 0.001) larger 
adipocytes in WT mice on HFD vs. WT mice on CD; Significantly (###p < 0.05) smaller 
adipocytes in HFD-fed NOX2KO mice vs. HFD-fed WT mice. Figure 2.3-C: 
Representative images of H&E stained adipocytes from which adipocyte size measures 
were based likewise revealed smaller adipocytes in HFD-fed NOX2KO mice compared 
with HFD-fed WT mice. 
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significant effect of genotype on visceral adipocyte size, there was a significant 
interaction of diet and genotype (F(1,34) = 15.18, p < = 0.0015), and post hoc tests 
showed that HFD-fed WT mice had larger epididymal adipocytes (Fig 2.3-B). Planned 
comparisons revealed that HFD-fed NOX2KO mice had significantly smaller epididymal 
adipocytes than HFD-fed WT mice (Fig 2.3-B), with no differences in visceral adipocyte  
size between CD-fed mice. Representative images of hematoxylin and eosin-stained 
tissue sections prepared from visceral epididymal adipose depots (Fig 2.3-C). 
 Obesity is frequently accompanied by chronic low-grade inflammation (Berg and 
Scherer, 2005; Hotamisligil, 2006), and evidence suggests that macrophages may 
mediate inflammatory pathways initiated within adipose tissues (Weisberg et al, 2003). 
Thus, macrophage infiltration into inguinal and epididymal adipose depots was 
evaluated by measuring expression of Iba-1, a calcium-binding protein specifically 
expressed in macrophages that is upregulated with activation (Hilton et al, 2008; Lee et 
al, 2008; Zecca et al, 2008) and can be used in Western blot and immunohistological 
analyses in paraffin-embedded tissues (Ahmed et al, 2007; Vega-Avelaira et al, 2007). 
Evaluation of Western blots indicated lower Iba-1 expression in NOX2KO mice, but not 
WT mice, adipose following HFD (Fig 2.4-B). Quantification and two-tailed, unpaired t-
test analyses of Iba-1 expression over multiple blots likewise revealed that HFD-fed 
mice had significantly higher Iba-1 expression in subcutaneous inguinal fat depots 
collected from both WT (t(18) = 4.43, p = 0.0003) and NOX2KO mice (t(18) = 3.17, p = 
0.0053; Fig 2.4-A)). Conversely, HFD-fed mice had higher visceral epididymal Iba-1 
expression only in WT (t(18) = 2.75, p = 0.0132) but not NOX2KO mice (Fig 2.4-A). 
Representative images of hematoxylin and eosin-stained tissue sections prepared from  
 34 
 
 
Figure 2.4: Effects of HFD on macrophage infiltration into adipose depots in WT and 
NOX2KO mice. Iba-1 expression was used to measure macrophage 
infiltration/activation in inguinal and epididymal fat. Data were collected from 10 mice in 
each group except for the NOX2KO/HFD group, which had 9 samples. Significant 
effects of diet are indicated with “*” (*p < 0.05, **p < 0.01, and ***p < 0.001). Figure 2.4-
A: HFD-induced Iba-1 expression in inguinal and epididymal adipose tissue in WT and 
NOX2KO mice as percentage of expression in CD mice. Significant (*p < 0.05) HFD-
induced higher Iba-1 expression in inguinal and epididymal fat in WT mice and inguinal 
fat in NOX2KO mice. Figure 2.4-B: Representative Western blot images showing Iba-1 
(17 kDa) expression in epididymal fat taken from WT and NOX2KO mice given CD or 
HFD. Figure 2.4-C: Representative images of Iba-1 immunostaining showing 
macrophage activation and infiltration into epididymal fat taken from WT and NOX2KO 
mice given CD or HFD. 
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visceral epididymal adipose depots likewise confirmed lower macrophage infiltration into 
adipose isolated from HFD-fed NOX2KO mice but not from HFD-fed WT mice or mice 
given CD (Fig 2.4-C). 
Diet-induced alterations to visceral adipocyte physiology in WT and NOX2KO mice 
 To determine whether the hypertrophy and inflammation noted in visceral 
adipose were accompanied by derangement in adipocyte physiology, markers of 
adipocyte function/injury in visceral adipose of WT and NOX2KO mice were examined 
by Western blot. Specifically, the overall expressions of PPARγ and adiponectin were 
evaluated, as they are both markers of mature functional adipocytes and also because 
loss of these factors contributes to obesity-induced metabolic decline (Aprahamian and 
Sam, 2011; Semple et al., 2006). Quantification and analyses of PPARγ expression 
revealed that HFD-fed mice had less expression of PPARγ relative to expression in CD-
fed mice only in WT (t(18) = 3.72, p = 0.0040) mice but not in NOX2KO mice (Fig 2.5-A). 
Conversely, adiponectin expression was less in HFD-fed mice in visceral fat depots 
collected from both WT (t(18) = 10.21, p < 0.0001) and NOX2KO mice (t(18) = 5.2, p < 
0.0001; Fig 2.5-B), and data also showed that the effect of HFD was significantly lower 
in NOX2KO mice than in WT mice (t(18) = 2.79, p = 0.0122; Fig 2.5-B). 
 Adipocyte injury was estimated by evaluating the expressions of 
GADD153/CHOP and GRP78, both of which are known to be increased in the context 
of obesity and thought to reflect endoplasmic reticulum (ER) stress in adipocytes 
caused by chronic and/or excessive inflammation (Oyadomari and Mori, 2004; Ozcan et 
al., 2004). Evaluation and statistical analysis of GADD153/CHOP blots revealed that 
HFD-fed mice had significantly higher GADD153 expression only in WT mice (t(18) =  
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Figure 2.5: Effects of HFD on markers of adipocyte function and injury in WT and 
NOX2KO mice. Expression of (Figure 2.5-A) PPARγ, (Figure 2.5-B) adiponectin, (Figure 
2.5-C) GADD153/CHOP, and (Figure 2.5-D) GRP78 were evaluated in tissue 
homogenates prepared from epididymal adipose depots. Data were collected from 10 
mice in each group except for the NOX2KO/HFD group, which had 9 samples, and 
depict means ± SE expression in HFD mice presented as percentage values in CD mice 
(100% line on graph). Significant effects of diet are indicated with “*” (*p < 0.05, **p < 
0.01, and ***p < 0.001), while significant effects of genotype are indicated with “#” (#p < 
0.05, ##p < 0.01, and ###p < 0.001). Significant (*p < 0.05, **p < 0.01, ***p < 0.001, 
respectively) changes in expression in HFD mice vs. CD mice; Significantly (#p < 0.05) 
higher expression in adiponectin in NOX2KO-HFD adipose vs. changes in expression in 
WT-HFD mice. 
 
3.77, p = 0.0014) but not in NOX2KO mice (Fig 2.5-C).  Likewise, expression of GRP78 
was also higher in HFD-fed WT mice (t(18) = 2.5, p = 0.0217; Fig 2.5-D) but not in 
NOX2KO mice (Fig 2.5-D). 
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Histological pattern of NOX2 expression in visceral adipose of WT mice 
 Although the above data indicate that NOX2 expression participates in HFD-
induced adiposopathy, these data do not give any indication as to the cell type(s) 
mediating this effect. This issue is noteworthy because, while NOX2 expression has 
been detected in white adipose depots in both rodents (Sakurai et al., 2009) and 
humans (Catalan et al., 2011), NOX2 expression in differentiated 3T3-L1 adipocyte cells 
appears to quite low (Han et al., 2012). Indeed, cell culture data indicate that NADPH 
oxidase-based signaling in adipocyte cell lines may be mediated by NOX4 rather than 
NOX2 (Mahadev, 2004; Schroder, 2009), raising the possibility that adipose NOX2 
expression may be restricted to macrophages, which are well known to be NOX2 
positive (Forman and Torres, 2002). To thus better understand how NOX2 regulates 
adipose function, the expression of NOX2 was evaluated immunohistochemically in 
visceral epididymal tissue isolated from CD- and HFD-fed WT mice as described 
in Materials and Methods. Initial experiments verified the specificity of the selected 
NOX2 antibody by showing that it was unable to recognize an epitope in NOX2KO 
adipose tissues (Fig 2.6-A). Qualitative evaluation of NOX2 expression in the visceral 
adipose sections demonstrated prominent NOX2 immunoreactivity in cells with 
morphology typical of macrophages (Fig 2.6-B). To more accurately confirm the cell 
type-specific pattern of NOX2 expression, sections from CD- and HFD-fed WT mice 
were double-labeled for NOX2 and the macrophage markers Iba-1. Evaluation of tissue 
double-labeled sections showed extensive colocalization of NOX2 and Iba-1 staining 
(Fig 2.6-B), indicating that macrophages are the predominant cell type expressing 
NOX2 in the visceral adipose depot. However, an occasional and less intense pattern of  
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Figure 2.6: Expression of NOX2 in visceral adipose of WT mice. Figure 2.6-A: 
Representative images of NOX2 Western blot showing that the antibody used for 
immunostaining did not recognize epitopes in NOX2KO tissue. Figure 2.6-B: 
Representative images of NOX2 immunoreactivity (left, red), Iba-1 immunoreactivity 
(middle, black), and NOX2/Iba-1 double-labeled sections (right) of epididymal fat taken 
from WT mice given CD or HFD. Images reflect the predominant expression of NOX2 in 
Iba-1-positive macrophages, although NOX2-positive, Iba-1-negative cells can be 
observed (arrows in right) perhaps arising from preadipocytes or other stromovascular 
cells.    
 
NOX2 immunoreactivity that was not associated with Iba-1-positive cells could be 
observed (Fig 2.6-B, arrows), perhaps arising from preadipocytes or other 
stromovascular cells. 
Diet-induced metabolic dysfunction in WT and NOX2KO mice 
 To determine the extent of HFD-induced metabolic syndrome in WT and 
NOX2KO mice, data were collected, and for presentation purposes are thematically 
divided into syndromes separately describing insulin resistance and hyperlipidemia. To 
document insulin sensitivity and glycemic control, studies focused on regulation of 
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fasting glucose and glucose tolerance. At the end of the 14-wk diet regimen, mice were 
fasted, and blood glucose and serum insulin were measured as described in Materials 
and Methods. Two-way ANOVA on the effects of genotype and diet on fasting blood 
glucose revealed significant main effects of diet (F(1,35) = 14.44, p = 0.0014) and 
genotype (F(1,35) = 35.67, p < 0.0001), with a statistically significant interaction between 
diet and genotype (F(1,35) = 6.72, p = 0.0239; Fig 2.7-A). Post hoc tests showed that 
HFD-fed mice had higher glucose levels in WT mice but not in NOX2KO mice, while 
planned comparisons revealed that glucose levels in HFD-fed NOX2KO mice were 
significantly lower than levels in HFD-fed WT mice (Fig 2.7-A). Conversely, two-way 
ANOVA on the effects of genotype and diet on fasting insulin revealed a significant 
effect of diet (F(1,35) = 14.44, p = 0.0014) but no effect of genotype and no interaction 
(Fig 2.7-B). Glucose tolerance was measured by OGTT as described in Materials and 
Methods, and statistical analyses showed significant main effects of diet (F(1,35) = 
42.96, p < 0.0001) and genotype (F(1,35) = 5.83, p = 0.0401) on glucose tolerance but no 
significant interaction between diet and genotype (Fig 2.7-C). Post hoc tests showed 
that HFD impaired glucose tolerance (i.e., increased the area under the curve) in both 
WT and NOX2KO mice, but planned comparisons revealed that HFD-fed NOX2KO 
mice had a smaller area under the curve compared with HFD-fed WT mice (Fig 2.7-C). 
Finally, in light of evidence of adipocyte hypertrophy and inflammation in HFD-fed WT 
mice, experiments were designed to reveal alterations in adipocyte glucose tolerance. 
Specifically, the adipose lipolytic response to glucose loading was evaluated by 
quantifying serum levels of NEFA at both fasting and 60 min post-glucose conditions, as 
described in Materials and Methods. Fasting NEFA levels (measured as meq/dl) were  
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Figure 2.7: Effects of HFD on glucose regulation and tolerance in WT and NOX2KO 
mice.  Mice were fasted for 4 h, after which an OGTT was performed to measure 
glucose regulation and insulin resistance. Data were collected from 10 mice in each 
group except for the NOX2KO/HFD group, which had 9 samples. Significant effects of 
diet are indicated with “*” (*p < 0.05, **p < 0.01, and ***p < 0.001), while significant 
effects of genotype are indicated with “#” (#p < 0.05, ##p < 0.01, and ###p < 0.001). 
Figure 2.7-A: Fasting blood glucose levels measured in WT and NOX2KO mice after 
administration of a HFD or CD. Significantly (***p < 0.001) higher fasting blood glucose 
level in HFD-fed WT vs. CD-fed WT mice; Significantly (###p < 0.001) lower fasting 
glucose in HFD-fed NOX2KO vs. HFD-fed WT mice. Figure 2.7-B: Fasting insulin levels 
measured in WT and NOX2KO mice after administration of a HFD or CD. Significantly 
(***p < 0.001) higher fasting insulin in WT mice on HFD vs. WT mice on CD, and 
similarly an increase in NOX2KO mice on HFD vs. NOX2KO mice on CD. Figure 2.7-C: 
Oral glucose tolerance, as indicated by area under the curve (AUC). Significantly (***p < 
0.001) larger AUC in WT mice on HFD vs. WT mice on CD; Significantly (*p < 0.05) 
larger AUC in NOX2KO mice on HFD vs. NOX2KO mice on CD. Significantly (#p < 
0.05) smaller glucose AUC in HFD-fed NOX2KO mice vs. HFD-fed WT mice.  Fig 2.7-D: 
NEFA levels in mice 60 min after glucose (2 mg/kg) gavage. Significantly (*p < 0.05 and 
***p < 0.001, respectively) higher serum levels of NEFA in HFD mice; Significantly (##p 
< 0.01) lower levels of NEFA following glucose load in HFD-fed NOX2KO vs. HFD-fed 
WT mice.   
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not significantly affected by genotype or diet (WT-CD, 1.139 ± 0.054; WT-HFD, 1.1070 
± 0.044; NOX2KO-CD, 1.140 ± 0.027; NOX2KO-HFD, 1.060 ± 0.068). However, while 
glucose administration decreased NEFA in CD-fed mice, post-glucose NEFA levels in 
HFD-fed WT were much higher than in other groups of mice (Fig 2.7-D). Specifically, 
ANOVA analyses of post-glucose NEFA levels showed a significant main effect of diet 
(F(1,33) = 42.96, p < 0.0001) and of genotype (F(1,33) = 5.83, p = 0.0401) on post-glucose 
NEFA but no interaction (Fig 2.7-D). Post hoc tests revealed that HFD increased post-
glucose levels of NEFA in both WT and NOX2KO mice, but planned comparisons 
showed that post-glucose NEFA were significantly lower in HFD-fed NOX2KO mice 
than in HFD-fed WT mice (Fig 2.7-D). 
 Studies next assessed a panel of bioactive serum lipids in WT and NOX2KO 
mice, measured under fasted conditions as described in Materials and Methods. Data 
showed a significant effect of diet (F(1,34) = 44.49, p < 0.0001) on total cholesterol, but no 
effect of genotype, no interaction, and no significant differences between WT and 
NOX2KO mice (Table 2.1). Likewise, there were significant effects of diet on LDL-
cholesterol (F(1,34) = 26.17, p = 0.0013) and on HDL-cholesterol (F(1,34) = 30.13, p = 
0.0004) but no effects of genotype and no interactions. Additionally, post hoc tests 
showed that HFD-fed mice had more LDL- and HDL-cholesterol species in WT but not 
in NOX2KO mice (Table 2.1). Finally, there were no differences in levels of fasting 
triglycerides or NEFA in either WT or NOX2KO mice given either CD or HFD (Table 
2.1). 
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Table 2.1.  Serum lipids in WT and NOX2KO mice following CD or HFD   
 
 WT NOX2KO 
CD HFD CD HFD 
Total Cholesterol (mg/dl) 151.4 ± 8.8 211.5 ± 11.7*** 159.0 ± 7.1 204.7 ± 11.0** 
LDL Cholesterol(mg/dl) 28.3 ± 1.1 36.5 ± 1.1* 29.9 ± 2.1 35.2 ± 3.0 
HDL Cholesterol(mg/dl) 80.0 ± 2.8 100.3 ± 4.6** 88.1 ± 4.0 100.9 ± 5.0 
Triglycerides(mg/dl) 29.2 ± 1.5 24.2 ± 3.7 25.2 ± 2.3 23.3 ± 2.7 
NEFA (mEq/L) 1.13 ± 0.05 1.07 ± 0.04 1.14 ± 0.03 1.07 ± 0.07 
 
Values are means +/- SE of data collected from 9-20 animals. Male wild-type (WT; 
C57BL/6) and NADPH oxidase subunit 2-deficient (NOX2KO) mice were administered 
control diet (CD) or high-fat diet (HFD) for 14 weeks, and then serum lipids were 
measured under fasted conditions as described in Materials and Methods. Data were 
analyzed by 2-way ANOVA followed by planned Bonferroni posttests to determine  
effects of HFD in NOX2KO vs. WT mice. Significant differences (*p < 0.05, **p < 0.01, 
and ***p < 0.001, respectively) noted in mice given HFD vs. CD mice. 
 
Effects of HFD on brain injury in WT and NOX2KO mice 
 Experiments were next designed to determine the extent of brain injury caused 
by HFD in both strains of mice. Analyses were thematically split into evaluations of 
cerebrovascular integrity, synaptic density, and reactive gliosis measured in the anterior  
neocortex, a CNS site of increased NOX activity/expression following HFD (Bruce-Keller 
et al., 2010).  Cerebrovascular and blood-brain barrier (BBB) integrity were evaluated by 
measuring the expressions of the essential tight junction proteins claudin-5, ZO-1, and 
occludin, as well as the matrix metalloproteinases MMP2 and MMP9, via Western blot, 
as described in Materials and Methods. These specific signals were chosen because 
lower expression of tight junction proteins is well known to accompany many 
neurological disorders including multiple sclerosis, stroke, Alzheimer's disease, 
Parkinson's disease, and epilepsy (Bednarczyk and Lukasiuk, 2011), while MMP are 
well known to degrade basement membranes and connective tissue of the BBB during 
inflammatory responses, contributing to both loss of BBB integrity and cerebral 
hypoperfusion (Nakaji et al., 2006). Western blot data indicated cerebrovascular injury 
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in WT but not NOX2KO mice following HFD (Fig 2.8). Specifically, two-tailed unpaired t-
tests revealed significantly lower expression in HFD-fed mice of claudin-5 (t(18) = 
2.75, p = 0.0191) and occludin (t(18) = 6.53, p < 0.0001) in WT but not NOX2KO mice  
(Fig 2.8-A). Likewise, MMP2 expression was higher (t(18) = 3.21, p = 0.0048) in HFD-fed 
WT mice but not NOX2KO mice (Fig 2.8-A), while ZO1 and MMP9 were not affected by 
diet in either strain of mice (Fig 2.8-A). 
 Evaluations of synaptic density were based on expression of the postsynaptic 
marker synapse-associated protein-97 (SAP97) and total and phosphorylated forms of 
the presynaptic protein synapsin 1 (SYN1). Quantification of total SYN1 expression 
revealed no differences in expression between groups (Fig 2.8-B), but levels of 
phosphorylated SYN1 (t(18) = 2.86, p = 0.0104) and SAP97 expression (t(18) = 2.34, p = 
0.0309) were significantly lower in HFD-fed WT mice but not NOX2KO mice (Fig 2.8-B). 
 To determine whether HFD consumption affected inflammatory gliosis in mice, 
the expression of astrocyte and microglial markers, as well as the proinflammatory/pro-
oxidant enzymes inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2), 
were evaluated in cortical homogenates by use of Western blot. The intermediate 
filament protein glial fibrillary acidic protein (GFAP) was used to evaluate astrocyte 
hypertrophy (O’Callaghan and Sriram, 2005), and data showed significantly higher 
expression in GFAP caused by HFD in WT (t(18) = 7.58, p < 0.0001; Fig 2.8-C) but not 
NOX2KO mice. Microglial reactivity was evaluated by measuring expression of Iba-1, 
and blots likewise revealed significantly higher Iba-1 expression following HFD in WT 
mice (t(18) = 2.62, p = 0.0174; Fig 2.8-C) but not in NOX2KO mice. iNOS and COX2 
were not affected by diet (Fig 2.8-C). 
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Figure 2.8: Effects of HFD on markers of brain injury in WT and NOX2KO mice. 
Significant effects of diet are indicated with “*” (*p < 0.05, **p < 0.01, and ***p < 0.001). 
Figure 2.8-A: Markers of cerebrovascular integrity (expression of the tight junction 
proteins claudin-5, ZO-1, and occludin and matrix metalloproteinases MMP2 and 
MMP9). Figure 2.8-B: Synaptic density [expression of postsynaptic marker protein 
synapse-associated protein-97 (SAP97), presynaptic protein synapsin 1, and 
phosphorylated synapsin 1] were evaluated in tissue homogenates prepared from the 
frontal cortex. Figure 2.8-C: Reactive gliosis (expression of GFAP, Iba1, iNOS, COX2). 
Data were collected from 10 mice in each group except for the NOX2KO/HFD group, 
which had 9 samples, and depict means ± SEM expression in HFD mice presented as 
%values in CD mice (100% line) on graph. Significant (*p < 0.05, **p < 0.01, ***p < 
0.001, respectively) changes in expression in WT HFD vs. WT CD mice. 
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 While NOX2KO mice have been used in numerous studies of brain injury, 
including models of aging (Park et al., 2007), stroke (Chen et al., 2011), Alzheimer's 
disease (Park et al., 2008), and traumatic injury (Dohi et al., 2010), systematic, side-by-
side comparisons of markers of cerebrovascular integrity, synaptic density, and reactive 
gliosis in WT and NOX2KO mice have not been reported. This is an important issue, as 
not only is NADPH oxidase thought to contribute to brain injury, but data also show that 
NADPH oxidase participates in synaptic plasticity and memory formation (Kishida and 
Klann, 2007; Kishida et al., 2005; Tejada-Simon et al., 2005), raising the possibility that 
compensatory changes in CNS physiology caused by genetic deletion of NOX2 could 
confound comparisons between WT and NOX2KO animals. Thus, to determine whether 
NOX2 deletion results in significant alterations in the murine CNS, tissue homogenates 
were prepared from the anterior cerebral cortex of WT and NOX2KO mice maintained 
on CD and were evaluated for markers of cerebrovascular integrity, synaptic density, 
and reactive gliosis, as described in Materials and Methods. Data show that claudin-5 
(t(18) = 2.42, p = 0.0264) and occludin expression (t(18) = 4.27, p+ 0.0005) were 
significantly lower in NOX2KO mice compared with WT mice (Table 2.2). Conversely, 
the expressions of all other cerebrovascular, synaptic, and glial/inflammatory markers 
were not significantly altered in NOX2KO mice compared with WT mice (Table 2.2). 
2.4 Discussion  
 
 Our findings strongly support a key role for NOX2 in the detrimental effects of 
diet-induced obesity. Specifically, we found that, while both WT and NOX2KO mice 
became obese following HFD administration, NOX2KO mice had attenuated adipose 
pathology and preserved adipose function, particularly in visceral adipose deposits.  
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Table 2.2. Effects of NOX2KO on baseline values for markers of brain injury 
 % WT 
Markers of Cerebrovascular Injury  
Claudin-5 79.6 ± 5.4# 
Occludin  71.3 ± 6.3### 
ZO-1 121.1 ± 12.6 
MMP2  111.7 ± 7.4 
MMP9 126.4 ± 17.8 
Markers of Synaptic Injury   
Phosphorylated Synapsin 96.0 ± 4.3 
Total Synapsin 109.7 ± 7.6 
SAP97 94.8 ± 3.2 
Markers of Reactive Gliosis  
GFAP 116.7 ± 13.8 
Iba-1 108.7 ± 6.9 
iNOS 83.1 ± 9.2 
COX2 79.1 ± 9.5 
 
Data show means ± SEM expression in NOX2KO mice presented as % WT and were 
analyzed by 2-tailed, unpaired t-tests. Tissue homogenates were prepared from the 
anterior cerebral cortex of male WT (C57BL/6) and NOX2KO mice maintained on CD 
were evaluated for markers of cerebrovascular integrity, synaptic density, and reactive 
gliosis as described in Materials and Methods. MMP, matrix metalloproteinase; SAP97, 
synapse-associated protein-97; GFAP, glial fibrillary acidic protein; COX2, 
cyclooxygenase 2. Significant differences (#p < 0.05 and ###p < 0.001, respectively) 
noted in NOX2KO mice vs. WT mice.   
 
Additionally, glucose tolerance was normalized in NOX2KO mice compared with WT 
mice following HFD, and HFD-induced brain injury was prevented in NOX2KO mice. 
Overall, these data are consistent with previous studies demonstrating higher NADPH 
oxidase activity/expression in models of obesity (Bruce-Keller et al., 2010; Chinen et al., 
2007; Zhang et al., 2005) and are also in agreement with the growing body of literature 
describing the sensitivity of the brain to obesity-induced metabolic dysfunction (Bruce-
Keller et al., 2009; Middleton and Yaffe, 2009). Moreover, these data significantly 
enhance the findings of previous studies with the demonstration that NOX2 is a specific 
and powerful mediator of pathogenic effects of diet-induced obesity that extend from 
adipocytes to brain cells. These detrimental effects could arise from NOX2-positive 
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visceral adipose macrophages, whose action precipitates loss of adipocyte function and 
the development of ER stress within adipose tissues, triggering pathways that may 
ultimately result in loss of metabolic and neurological function. Collectively, our findings 
raise the possibility that NOX2-based therapies could be used clinically to preserve both 
metabolic and neurological function in the context of obesity. 
 These data support a key role for NOX2 in adipose responses to HFD. Visceral 
adipose deposits from HFD-fed NOX2KO mice were smaller, with less hypertrophy and 
macrophage infiltration, compared with WT mice given HFD. These data also show that 
NOX2 deletion attenuates the development of ER stress in adipose tissues and also 
preserves the expression of mature adipocyte markers, suggesting that sustained 
expression/activity of NOX2 leads to an overall destabilization of adipocyte physiology 
through ER stress. These data are in agreement with existing literature on the role of 
free radicals in general, and NADPH oxidase specifically, in adipocyte physiology. For 
example, many studies have established that HFDs increase adipose NADPH oxidase 
(Coate and Huggins, 2010; Furukawa et al., 2004; Matsuzawa-Nagata et al., 2008) and 
that NADPH oxidase regulates adipocyte chemokine expression (Furukawa et al., 
2004; Han et al., 2012), which could explain our observations of less macrophage 
infiltration into NOX2-deficient adipose. Data also support an important role for NADPH 
oxidase in long-term adipocyte responses to insulin, such as proliferation and 
differentiation (Schroder et al., 2009); however, this paper is the first to provide 
evidence for a specific role for NOX2 in these pathways. The human genome contains 
five NOX members, NOX1 through NOX5 (Geiszt and Leto, 2004; Lambeth, 2004).  And 
while NOX2 expression is found in white adipose deposits in both rodents (Sakurai et 
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al., 2009) and humans (Catalan et al., 2011), NOX2 expression in differentiated 3T3-L1 
adipocytes appears to be quite low (Han et al., 2012), raising questions as to which 
adipose-resident cells express NOX2. Indeed, cell culture data indicate that many of the 
free radical-based pathways involved in adipocyte insulin sensitivity and proliferation 
may be mediated by NOX4 rather than NOX2 (Mahadev et al., 2004; Schroder et al., 
2009). However, in contrast to the protective effects of NOX2 deletion reported here, 
NOX4-deficient mice have recently been shown to have enhanced susceptibility to diet-
induced obesity, with accelerated insulin resistance, enhanced adipocyte hypertrophy, 
and increased adipose tissue hypoxia, inflammation and apoptosis (Li et al., 2012). 
These findings thus suggest differential roles for the NADPH oxidase subunits in 
adipose tissue, with NOX4 involved in maintaining physiological events such as insulin 
receptor signaling and adipocyte proliferation/differentiation, and NOX2 driving 
sustained inflammatory changes in response to stimuli like fatty acids or oxidized 
lipoproteins. 
 These data also suggest that NOX2 might play a particularly deleterious role 
specifically in visceral adipose. Subcutaneous and visceral adipocytes derive from 
different progenitor cells that exhibit a different gene expression pattern and thus may 
respond quite differently to the effects of diet or NADPH oxidase inhibition. Indeed, 
visceral fat tissue is strongly associated with insulin resistance, diabetes mellitus, 
dyslipidemia, hypertension, atherosclerosis, hepatic steatosis, and overall mortality, 
whereas subcutaneous fat seems to have intrinsic beneficial metabolic properties (Gil et 
al., 2011). While the reasons for this are not yet clear, several studies have documented 
that visceral adipose is distinguished by increased inflammation. For example, the 
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number of macrophages has been estimated at two- to four-fold higher in visceral 
compared with subcutaneous fat irrespective of adiposity levels (Harman-Boehm et al., 
2007); likewise, the expression of proinflammatory cytokines is elevated in visceral 
compared with subcutaneous fat (Atzmon et al., 2002). This relatively enhanced level of 
inflammation in the visceral fat has been repeatedly and directly linked to obesity-
related insulin resistance and type 2 diabetes (Hotamisligil and Erbay, 2008; Shoelson 
et al., 2006). For example, the cytokine TNFα has been demonstrated to mediate 
obesity-induced insulin resistance (Hotamisligil, 1999), while the chemokine monocyte 
chemotactic protein-1 (MCP-1) has also been shown to impair adipocyte insulin 
sensitivity (Sartipy and Loskutoff, 2003). Increased proinflammatory cytokines can 
induce insulin resistance by several mechanisms, including via suppression of cytokine 
signaling-3 (SOCS3) expression (Emanuelli et al., 2001) and/or the activation of 
numerous intracellular serine kinases such as c-Jun NH2-terminal kinase (JNK) and 
inhibition of κB kinase (IKK) (Hirosumi et al., 2002). Finally, it is important to note that 
data from our laboratories and others' have firmly established the critical role that 
NADPH oxidase plays in directing macrophage inflammation, particularly the release of 
proinflammatory cytokines including TNFα, IL-6, and IL-1β (Clark and Valente, 
2004; Robertson et al., 1990; Turchan-Cholewo et al., 2009). Thus, the data in this 
paper raise the possibility that inhibition of NOX2 just within visceral adipose may be 
sufficient to prevent the pattern of macrophage accumulation and inflammation that 
precipitates metabolic and neurological decline. This finding is both highly clinically 
significant and easily translated into new therapies. 
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 While obesity is known to predispose individuals to a myriad of diseases (Haslam 
and James, 2005), the brain may be one of the more critical sites in light of the 
increasing costs associated with cognitive impairment and dementia. These data 
indicate that NOX2 may be a key aspect of diet-induced brain injury, in agreement with 
a large body of literature supporting a role for NADPH oxidase in neurodegenerative 
pathways (Block, 2008; Lambeth, 2007; Shimohama et al., 2000). For example, the 
same NOX2KO mice are protected from postischemic neuroinflammation and 
inflammatory cytokine-mediated brain damage (Chen et al., 2011) and also from 
microglia-mediated injury in mouse models of traumatic brain injury (Dohi et al., 2010), 
indicating that NOX2 mediates neurotoxic brain inflammation. In further support of this 
potential mechanism, data from our laboratories and others' have established the critical 
role that NOX2 plays in the release of proinflammatory cytokines including TNFα, IL-6, 
and IL-1β (Clark and Valente, 2004; Robertson et al., 1990; Turchan-Cholewo et al., 
2009), all of which could underlie neurological impairment (Akiyama et al., 2000; Arvin 
et al., 1996; Lane et al., 1996; Parnet et al., 2002; Tyor et al., 1992). Although cytokine 
expression was not documented in this study, data show that HFD-induced reactive 
gliosis was prevented in NOX2KO mice, and previous studies from our laboratory show 
a tight association of reactive gliosis with both CNS cytokine release and cognitive 
impairment following HFD (Pistell et al., 2010). Interestingly, however, NADPH oxidase 
also participates in physiological events including neuronal signaling and memory 
formation (Kishida and Klann, 2007; Kishida et al., 2005; Tejada-Simon et al., 2005). 
Cognitive function was not measured in this study, since both humans and mice with 
similar NOX2 mutations have been shown to have some degree of cognitive dysfunction 
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(Kishida et al., 2006; Pao et al., 2004). In this regard, the lack of significant differences 
in basal expression of synaptic markers suggests that cognitive deficits associated with 
NOX2KO likely reflect alterations in synaptic signaling rather than decreases in synaptic 
number, which is in keeping with current thoughts on the role of NADPH oxidase in 
cognition (Ali et al., 2011; Knapp and Klann, 2002). Collectively, these data raise the 
possibility that neurological function would be best preserved if the proinflammatory, 
detrimental consequences of glial NOX activation could be inhibited while preserving 
physiological neuronal NOX signaling. Indeed, genetically engineered mice with LoxP 
sites flanking the NOX2 gene are currently under development, and these mice may 
significantly advance understating of the complex and nuanced role of NOX2 in the 
brain. It should also be pointed out that commercially available NOX2KO mice have 
been available as homozygous breeders for many years, raising the possibility of subtle 
genetic drift between commercially available NOX2KO mice and the parental C57Bl/6 
strain, which could potentially contribute to reported differences between strains. 
Indeed, it is possible that genetic drift and/or compensatory changes in the expression 
of other NADPH oxidase subunits could be partially responsible for the alterations in 
basal claudin-5 and occludin expression noted in NOX2KO mice (see Table 2). The use 
of newly developed, tissue-specific NOX2 knockout mice could thus also circumvent 
any artifacts introduced by subtle genetic drift and/or compensatory changes in the 
NOX2KO and C57Bl/6 strains of mice. 
 One key site whereby aberrant and/or sustained NADPH oxidase activation could 
undermine brain function is in the cerebrovascular compartment. Indeed, data in this 
paper reveal that HFD-induced perturbations to cerebrovascular integrity (lower tight 
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junction protein/higher MMP expression) are blunted in NOX2KO mice. While direct 
cerebrovascular function was not measured in this study, numerous reports have 
confirmed that alterations in these markers faithfully reflect physiological impairments in 
BBB function (Liu et al., 2011; McColl et al., 2010). In addition to loss of BBB integrity, 
there is increasing evidence that hypoperfusion and/or loss of neurovascular coupling 
may be a key pathway whereby oxidative stress connects vascular-related diseases to 
cognitive impairment (Kim et al., 2012; Liu and Zhang, 2012). Indeed, evidence 
suggests that diabetes-induced cognitive decline may be induced via disruption of 
neurovascular coupling, with physiological impairment arising from both cerebrovascular 
elements and also glial cells (Mogi and Horiuchi, 2011; Serlin et al., 2011). In this light, it 
is important to note that NADPH oxidase is a major player in both endothelial and glial 
physiology. Overall, therefore, these data collectively support the hypothesis that 
excessive or sustained NADPH oxidase activation could disrupt brain homeostasis 
through any of several different cerebrovascular mechanisms, raising the possibility that 
targeted NOX2 inhibition could be a viable therapeutic strategy to preserve neurological 
function in the context of pathogenic obesity. 
 While NOX2KO mice were protected from many of the metabolic and 
neurological effects of HFD, it is clear that both strains of mice became obese in 
response to HFD.  Thus, these data reiterate that obesity per se is not sufficient to 
precipitate metabolic or neurological decline. This scenario is also reflected in clinical 
settings, but it remains unclear why increased adiposity appears to cause disease in 
some people but not in others (Bays et al., 2006). Recently devised theories posit that 
obesity in susceptible individuals is uniquely associated with pathological dysfunction in 
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adipocytes (sick fat or adiposopathy) and that these abnormalities in fat function, rather 
than increases in fat mass, precipitate physiological decline (Appachi et al., 2011; Bays 
et al., 2006; Bays et al., 2008). Adiposopathy is generally defined anatomically by 
adipocyte hypertrophy and physiologically by impaired fatty acid regulation (elevated 
release, particularly under high-glucose conditions), disrupted adipokine secretion, and 
increased inflammation (Appachi et al., 2011; Bays, 2005; Bays, 2011; Heilbronn et al., 
2004). Data in this paper suggest that NOX2 may mediate, at least in part, the 
pathological processes of adiposopathy. As obesity remains increasingly prevalent and 
seemingly resistant to clinical remediation (Padwal et al., 2004), these data suggest that 
new therapies to preserve health in the presence of obesity could be based on 
manipulation of NOX2. 
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Chapter 3. Deletion of Macrophage NOX2 Preserves Metabolic and 
Neurologic Health in Diet-Induced Obese Mice 
 
3.1 Introduction 
High fat diets and diet-induced obesity are major drivers of metabolic syndrome, 
which is associated with dramatically enhanced risk for many diseases including type 2 
diabetes, cardiovascular disease, stroke, and cancer (reviewed in (Haslam and James, 
2005)). While the pathogenesis of metabolic syndrome is not fully understood, obesity is 
closely associated with a pattern of chronic inflammation in adipose tissue (Shoelson et 
al., 2007), from which cytokines, acute-phase reactants, and other inflammatory 
mediators originate to elicit systemic inflammation (Berg and Scherer, 2005; Chandalia 
and Abate, 2007; Hotamisligil, 2006). For example, infiltration of macrophages into 
adipose tissue is well established following high-fat feeding (Weisberg et al., 2003; 
Apovian et al., 2008), and has been linked to increased inflammation as well as 
dyslipidemia and insulin resistance (Apovian et al., 2008). Activation of systemic 
inflammation is also associated with impaired brain function (Dziedzic, 2006; Trollor et 
al., 2012), and indeed, diet-induced obesity has also been linked to brain pathology, 
cognitive dysfunction, and Alzheimer’s disease (reviewed in (Olufadi and Byrne, 2008)).  
For example, data show impaired learning, memory, and executive function in obese as 
compared to nonobese patients (Elias et al., 2003; Elias et al., 2005; Waldstein and 
Katzel, 2006), and regression studies suggest that increased body weight might 
decrease brain volume (Ward et al., 2005) or disrupt the balance of white to grey 
matter, particularly in the frontal lobe (Pannacciulli et al., 2006).   
 While the molecular link(s) between excess adiposity and inflammation has not 
yet been identified, recent reports have implicated activation of the proinflammatory 
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enzyme NADPH oxidase in the detrimental effects of diet-induced obesity. NADPH 
oxidase is a superoxide-producing complex consisting of membrane (NOX2/gp91phox 
and p22phox) and cytosolic (p47phox, p67phox, and p40phox) components that 
assemble at the plasma membrane, where NOX2 transfers electrons from NADPH to 
molecular oxygen, producing a burst of superoxide (Babior, 1991; DeLeo and Quinn, 
1996). Studies show that NADPH oxidase activity/expression is increased in laboratory 
animals given high fat diet (Bruce-Keller et al., 2010; Coate and Huggins, 2010; Zhang 
et al., 2005; Furukawa et al., 2004; Matsuzawa-Nagata et al., 2008), and further indicate 
that diet-induced increases in NADPH oxidase mediate obesity-related proinflammatory 
cytokine and chemokine release as well as insulin resistance, hyperlipidemia, and liver 
steatosis (Furukawa et al., 2004; Han et al., 2012). Finally, mice deficient in NOX2 have 
been shown to be resistant to the detrimental effects of high fat diets, with attenuated 
adipose pathology and inflammation, and preserved adipose function, glucose 
tolerance, and cerebral homeostasis (Pepping et al., 2013).   
 While existing data support a role for NADPH oxidase in obesity-related 
inflammation, NADPH oxidase-based signaling pathways also play important roles in 
physiologic processes (Infanger et al., 2006; Sorce and Krause, 2009). Indeed, well-
established effects of systemic NOX2 deletion on cognitive function (Infanger et al., 
2006; Sorce and Krause, 2009) rule out broad-based NADPH oxidase inhibition as a 
viable therapeutic approach in obesity. Furthermore, recent expansion of the genome 
databases has identified several homologues of NOX2 (NOX1-5, DUOX1-2) that differ 
in their activation requirements and mediate diverse and pleiotropic actions (Lambeth, 
2004; Geiszt and Leto, 2004). Cell culture and animal data indicate that adipocyte 
 64 
function and insulin sensitivity requires NOX4 activity (Mahadev et al., 2004; Schröder 
et al., 2009; Li et al., 2012), suggesting opposing roles for NOX2 and NOX4 in obesity 
pathogenesis. To reveal the therapeutic potential of targeted NADPH oxidase inhibition, 
we generated mice with a floxed allele of the NAPDH oxidase subunit NOX2 and 
crossed these with mice expressing LysM-Cre to generate mice lacking NOX2 in all 
myeloid lineage cells, including monocytes, macrophages, and microglia. To reveal the 
role of macrophage-specific NADPH oxidase in the pathophysiology of obesity, a 
C57Bl/6 wild type (WT-FL) and macrophage-deficient NOX2 (macNOX2KO) mice were 
given high fat diet for 16 weeks, and subject to comprehensive metabolic, behavioral, 
and biochemical analyses. 
3.2 Materials and Methods 
Transgenic Animal Generation and Treatment   
 The Institutional Animal Care and Use Committee at the Pennington Biomedical 
Research Center approved all experimental protocols, which were compliant with NIH 
guidelines on the use of experimental animals. Novel transgenic mice with LoxP 
sequences on either side of exon 5 of the NOX2 gene (cybb) were generated on a 
C57Bl/6 background using standard procedures. Mice homozygous for floxed NOX2 
(WT-FL) were generated by serial crossings, and the presence of the LoxP sites was 
confirmed by genomic sequencing (data not shown). Female WT-FL were then crossed 
with male LysM-Cre transgenic mice purchased from Jackson Laboratory (Bar Harbor, 
ME, USA), to generate male F1 progeny lacking NOX2 specifically in myeloid lineage 
cells (macNOX2KO). Male macNOX2KO and WT-FL mice were then used for 
experimentation, and housed in standard caging with a 12:12 light:dark cycle and ad 
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libitum access to food and water. WT-FL and macNOX2KO mice were separated into 
groups given either high fat diet (HFD- 60% fat) or low fat control diet (CD- 10% fat) for 
16 weeks. Both diets are open source, were purchased from Research Diets (New 
Brunswick, NJ; HFD: D12492; CD: D12450B), and were provided in pelleted form. Data 
were compiled from 2 separate experiments, each composed of both WT-FL and 
macNOX2KO mice given CD or HFD, with 18-20 total animals in each group.    
Body weight, food intake, and body composition (measured using a Bruker 
minispec LF90 time domain Nuclear Magnetic Resonance (NMR) analyzer, Bruker 
Optics, Billerica MA) were measured 2 times a month. Fasting blood glucose was 
measured in tail blood using a glucometer (Ascensia Elite, Bayer, Mishawaka, IN). All 
mice were humanely euthanatized via isoflurane inhalation and cardiac exsanguination 
after a brief (6 hr) fast, and blood, brain (anterior 1/3 of cerebral cortex), visceral 
(epididymal), and subcutaneous (inguinal) adipose tissue depots were collected.  
Clinical Chemistry 
Whole blood was collected by cardiac exsanguination of terminally anesthetized 
mice, and was allowed to clot at 4ºC overnight and then centrifuged at 3000xg for 30 
minutes.  Serum was collected and either analyzed immediately or aliquoted and stored 
at -80ºC.  Levels of total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, 
and nonesterified fatty acids (NEFA) in sera were measured colorimetrically using 
commercially available kits (Wako Chemicals, Richmond, VA). Insulin levels were 
evaluated by ELISA in accordance with the manufacturer’s assay protocol (Crystal 
Chem Inc., Downers Grove IL).   
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Histological and biochemical analyses of adipose tissue 
The inguinal and epididymal adipose depots were collected for histological and 
biochemical analyses. For histology, the tissues were immersion-fixed in 10% neutral 
buffered formalin for 2-3 days, after which they were processed for paraffin embedding. 
Sections (5 µm) were then cut, stained with hematoxylin and eosin, and digitized.  
Adipocyte size was measured by an investigator blinded to the experimental grouping in 
40X microscope fields by counting the total number of adipocytes within predefined area 
grids, and then dividing the area by the total number of adipocytes within the grids to 
calculate average adipocyte size. For each sample, 3 tissue sections were analyzed, 
with 3 fields counted in each section, for an average of 9 fields per sample. For 
immunohistochemical analyses of macrophage crowns in adipose tissues, tissue 
sections were processed using anti-Iba-1 (1:100, Wako Chemicals, Richmond, VA). 
Sections were incubated with biotinylated-linked secondary antibodies, and then 
visualized using diaminobenzidine (Vector Laboratories, Burlingame, CA).  For Western 
blot, adipose tissue samples were homogenized in RIPA buffer (G biosciences, St. 
Louis, MO), and then cleared by centrifugation at 5000 x g for 10 minutes at 40C. 
Samples were denatured in SDS, and equivalent amounts of protein were 
electrophoretically separated in polyacrylamide gels and blotted onto nitrocellulose. 
Blots prepared from adipose tissue were processed using anti-GADD153/CHOP 
(1:5000, Abcam PLC), anti-GRP78 (1:500, Novus Biologicals LLC), and anti-total 
STAT5 (1:1000, Abcam PLC). After incubation with primary antibodies, blots were 
washed and exposed to horseradish peroxidase-conjugated secondary antibodies, and 
visualized using a chemiluminescence system (Amersham Biosciences, Pittsburgh, 
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PA). Blot images were scanned and densitometrically analyzed for quantification. To 
ensure accurate quantification across multiple blots, samples from all groups (HFD and 
CD in both WT-FL and macNOX2KO) were included in each individual blot. Data were 
calculated as a ratio of expression over tubulin expression, which was included as an 
internal loading control. Protein expression in HFD mice was then calculated and 
presented as percent expression relative to CD mice of the same genotype. 
Fear conditioning memory task 
Each mouse was individually evaluated for fear conditioning using an automated, 
video-based fear conditioning system (Med-Associates, St. Albans, VT) as described 
previously (Bruce-Keller et al., 2015; Pepping et al., 2014). The apparatus consists of a 
“startle chamber” used on days 1 and 2, which is an 8×15×15-cm acrylic and wire mesh 
cage located within a custom designed 90×70×70 ventilated sound-attenuating 
chamber, and the unique context is reinforced with an anise-based scent applied to 
each cage before testing. Animal movement within the apparatus results in 
displacement of an accelerometer (model U321AO2; PCB Piezotronics, Depew, NY, 
USA). Acquisition of fear conditioning on day 1 consists of 5 minutes acclimation to the 
startle chamber, followed by five consecutive 30 second auditory stimuli (85 db, 4 KHz) 
co-terminating with a mild footshock (0.5 mA × 1 sec), with 30 second recovery periods 
between tones. On day 2, mice return to the same chambers, but no stimuli are applied 
to evaluate freezing responses to context. On day 3, mice are placed in an entirely 
separate chamber located in a different room to remove all contextual cues, and after 5 
minute habituation, a continuous tone (85 db, 4 KHz) is applied for 5 minutes. Freezing 
behavior is recorded as a measure of memory of the conditioned response to the tone. 
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Statistical analyses 
All data are shown as mean ± standard error of measurement. Body weight and 
composition data, adipocyte size, and all metabolic data were all analyzed with 2-way 
analyses of variance (ANOVA), followed by planned Bonferroni post-tests to determine 
the effects of HFD in both WT-FL and macNOX2KO mice. Additional planned 
comparisons of WT-FL and macNOX2KO mice under both CD and HFD conditions 
were carried out to determine the effects of genotype under both diet conditions. 
Significant effects of diet are indicated with “*” (*p < 0.05, **p < 0.01, and ***p < 0.001), 
while significant effects of genotype are indicated with “#” (#p < 0.05, ##p < 0.01, and 
###p < 0.001). Protein expression values generated by Western blot (ratios of 
expression over tubulin) were normalized to percent CD for each genotype to reconcile 
data from multiple blots, and were analyzed by 2-tailed, unpaired t-tests to determine if 
statistically significant differences exist between HFD and CD groups within each 
genotype. 
3.3 Results 
Generation and characterization of macNOX2KO mice 
To determine the therapeutic potential of cell type-specific NOX2 deletion in diet-
induced obesity, newly engineered mice in which LoxP sequences were placed on 
either side of exon 5 of the NOX2 gene were generated (WT-FL). WT-FL mice were 
bred to homozygosity, and female WT-FL mice were mated with male LysM-Cre 
transgenic mice to generate male mice lacking NOX2 in all myeloid lineage cells 
(macNOX2KO). Male progeny from WT-FL crosses were used as controls, and there 
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were no differences in pregnancy rates, litter sizes, or sex balance of offspring between 
WT-FLxWT-FL and WT-FLxLysMCre breeding pairs (data not shown).   
Effects of HFD on body weight and composition in WT-FL and macNOX2KO mice 
4-month-old male WT-FL and macNOX2KO mice were fed either high fat diet 
(HFD) or low fat control diet (CD) for 16 weeks as described in Materials and Methods.  
During this time, body weights progressively diverged such that HFD-fed mice weighed 
significantly more than CD mice after 4 weeks (Fig 3.1-A). Statistically, ANOVA for 
genotype X diet at the end of exposure revealed a significant main effect of diet on body 
weight (F(1,68) = 104.3, p < 0.0001). The effect of genotype on body weight was also 
significant (F(1,68) = 20.02, p = 0. 0001), but the interaction was not. Planned 
comparisons of macNOX2KO and WT-FL mice revealed that while there were no 
significant differences between body weights in mice given CD, HFD-fed macNOX2KO 
mice weighed significantly less than HFD-fed WT-FL mice after 4 weeks of diet 
consumption (Fig 3.1-A). In addition to body weight, total body fat was measured using 
NMR as described in Materials and Methods. Similar to what was observed for body 
weight, total body fat (expressed as % total body weight) was higher in all mice over the 
16-week feeding trial, but mice given HFD had significantly more fat by 4 weeks of diet 
consumption (Fig 3.1-B). Statistically, ANOVA to measure the effects of genotype and 
diet on % body fat at the end of diet exposure revealed a significant main effect of diet 
(F(1,68) = 52.34, p < 0.0001), but no effect genotype and no significant interaction 
between diet and genotype on body fat. Planned comparisons of macNOX2KO and WT-
FL mice revealed no genotype-based differences in % body fat in mice given CD, but 
did reveal a lower body fat percentage in macNOX2KO as compared to WT-FL mice  
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Figure 3.1: Effects of high-fat diet (HFD) on body weight and composition in wild-type 
mice with floxed exon 5 of NADPH oxidase subunit 2 (WT-FL) and macrophage-
deficient NADPH oxidase subunit 2 knockout (macNOX2KO) mice. Four-month-old 
male WT-FL mice and macNOX2KO mice were placed for 16 wk on HFD or the 
nutritionally matched low-fat control diet (CD) with 18-20 mice in each group. Significant 
effects of diet are indicated with “*” (*p < 0.05, **p < 0.01, and ***p < 0.001), while 
significant effects of genotype are indicated with “#” (#p < 0.05, ##p < 0.01, and ###p < 
0.001). Figure 3.1-A: Body weight in WT-FL and macNOX2KO mice over time following 
administration of CD or HFD. Significantly (###p <0.001) lower body weight noted in 
macNOX2KO mice vs. WT-FL mice on HFD after 4 wk. Figure 3.1-B: Body fat as %total 
body weight in WT-FL and macNOX2KO mice over time following administration of CD 
or HFD. Significantly (##p < 0.01) lower body fat in macNOX2KO mice vs. WT-FL mice 
on HFD after 4 and 6 wk. Figure 3.1-C: Average food intake per mouse for WT-FL and 
macNOX2KO mice following administration of CD or HFD. Significantly (*p < 0.05) 
higher food intake for WT-FL mice on HFD vs. CD. Significantly (***p < 0.001) higher 
food intake for macNOX2KO mice on HFD vs. CD. 
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4 and 6 weeks of HFD (Fig 3.1-B). Analysis of food intake during this period was also 
conducted, and while data show that both strains of mice ate more HFD as compared to 
CD, there were no differences between WT-FL and macNOX2KO mice with regards to 
diet (CD or HFD) ingestion (Fig 3.1-C), indicating that NOX2 is not involved in feeding 
behavior and that the increased body weight in WT-FL mice was not caused by 
increased food intake.   
Diet-induced adipocyte inflammation, hypertrophy, and injury in WT-FL and 
macNOX2KO mice 
Accumulation of macrophages in adipose tissues elicits inflammation, which 
leads to both local and systemic insulin resistance and metabolic impairment (Weisberg 
et al., 2003; Apovian et al., 2008). As our recent data suggest that NOX2-positive 
macrophages might mediate obesity-induced inflammatory and pathogenic changes in 
adipose tissue, we next investigated the impact of conditional NOX2 deletion on 
macrophage infiltration into visceral adipose tissue by measuring expression of Iba-1, a 
calcium binding protein specifically expressed in macrophages that is unregulated with 
activation (Hilton et al., 2008; Lee et al., 2008; Zecca et al., 2008) and can be used in 
immunohistological analyses in paraffin-embedded tissues (Ahmed et al., 2007; Vega-
Avelaira et al., 2007). Blinded quantification of Iba-1-positive macrophages in crown-like 
structures (CLSs) within epididymal adipose depots was markedly increased following 
HFD, particularly in WT-FL mice (Fig 3.2-A). Specifically, ANOVA for the effects of 
genotype and diet on epididymal CLS revealed a significant main effect of diet (F(1,66) = 
50.11, p < 0.0001) and of genotype (F(1,66) = 16.20, p < 0.0001), with a significant 
interaction (F(1,66) = 11.02, p = 0.0015). Planned comparisons revealed no differences in  
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Figure 3.2: Effects of HFD on adipocyte inflammation, hypertrophy, and injury in WT-FL 
and macNOX2KO mice. Visceral epididymal fat pads were collected from WT-FL and 
macNOX2KO mice at the end of the 16-wk feeding trial and processed for analyses. 
Significant effects of diet are indicated with “*” (*p < 0.05, **p < 0.01, and ***p < 0.001), 
while significant effects of genotype are indicated with “#” (#p < 0.05, ##p < 0.01, and 
###p < 0.001). Figure 3.2-A: Number of Iba-1 positive macrophages in crown-like 
structures (CLS) in WT-FL and macNOX2KO mice after administration of CD or HFD. 
Significantly (***p < 0.001) higher number of CLS in WT-FL mice on HFD vs. CD. 
Significantly (*p < 0.05) higher number of CLS in macNOX2KO mice on HFD vs. CD. 
Significantly (###p < 0.001) lower number of CLS in macNOX2KO mice on HFD vs. 
WT-FL mice on HFD. Figure 3.2-B: Representative images of Iba-1 stained adipocytes 
used to determine number of CLS and adipocyte size. Figure 3.2-C: Size of visceral 
adipocytes in WT-FL mice and macNOX2KO mice after administration of CD or HFD. 
Significantly (**p < 0.01) larger adipocyte size in WT-FL mice on HFD vs. CD. 
Significantly (***p < 0.001) larger adipocyte size in macNOX2KO mice on HFD vs. CD. 
Significantly (#p < 0.05) smaller adipocyte size in macNOX2KO mice on CD vs. WT-FL 
mice on CD. Figure 3.2-D: Effects of HFD on markers of adipocyte injury in WT-FL and 
macNOX2KO mice. Significantly (***p < 0.001) higher levels of expression of CHOP and 
GRP78 in WT-FL mice on HFD vs. CD. Significantly (###p < 0.001) lower levels of 
expression of CHOP and GRP78 in macNOX2KO mice vs. WT-FL mice. 
 
 73 
the epididymal CLS number in CD-fed macNOX2KO compared to CD-fed WT-FL mice, 
but did show that HFD significantly increased the numbers of CLS in both WT-FL and 
macNOX2KO mice (Fig 3.2-A).  However, the number of CLS in HFD-fed macNOX2KO 
mice was significantly less that in HFD-fed WT-FL mice (Fig 3.2-A). Representative 
images of Iba-1 stained tissue sections reveal obviously increased Iba-1 positive CLS in 
visceral epididymal adipose depots isolated from HFD-fed WT-FL mice, but not from 
HFD-fed macNOX2KO mice or mice given CD (Fig 3.2-B).   
As obesity and metabolic dysfunction are frequently associated with adipocyte 
enlargement or hypertrophy (Bays et al., 2008; Heilbronn et al., 2004), the size of 
individual adipocytes within visceral epididymal adipose depots was evaluated in tissue 
sections as described in Materials and Methods. Such measures revealed that HFD-fed 
mice had significantly larger visceral adipocytes (Fig 3.2-C). Specifically, ANOVA for the 
effects of genotype and diet on epididymal adipocyte size revealed a significant main 
effect of diet (F(1,66) = 38.61, p < 0.0001), but no effect of genotype and no interaction. 
Planned comparisons revealed that epididymal adipocytes in CD-fed macNOX2KO 
mice were significantly smaller than adipocytes in CD-fed WT-FL (Fig 3.2-C).  However, 
HFD consumption resulted in larger visceral adipocytes similarly in both WT-FL and 
macNOX2KO mice (Fig 3.2-C). To determine if the hypertrophy and inflammation noted 
in visceral adipose was accompanied by derangement in adipocyte physiology, markers 
of adipocyte injury in visceral adipose of WT-FL and macNOX2KO mice were examined 
by Western blot. Specifically, adipocyte injury was estimated by evaluating the 
expression GADD153/CHOP and GRP78, both of which are known to be elevated in the 
context of obesity and thought to reflect endoplasmic reticulum (ER) stress in 
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adipocytes caused by excessive inflammation (Ozcan et al., 2004; Oyadomari and Mori, 
2004). Evaluation and statistical analysis of GADD153/CHOP blots revealed that HFD-
fed macNOX2KO mice had significantly lower levels of GADD153 expression (t(31) = 
4.55, p < 0.0001) as compared to WT-FL mice (Fig 3.2-D).  Likewise, expression of 
GRP78 was also lower in HFD-fed macNOX2KO mice (t(27) = 6.70, p < 0.0001; Fig 3.2-
D), than in WT-FL mice (Fig 3.2-D), suggesting that although adipocytes in 
macNOX2KO mice became hypertrophic, these cells did not appear to be subject to ER 
stress.   
Diet-induced metabolic dysfunction in WT-FL and macNOX2KO mice 
To determine the extent of HFD-induced metabolic syndrome in WT-FL and 
macNOX2KO mice, data were collected, and for presentation purposes are thematically 
divided into syndromes separately describing insulin resistance and hyperlipidemia. To 
document insulin sensitivity and glycemic control, studies focused on regulation of 
fasting glucose and glucose tolerance. At the end of the 16-week diet regimen, mice 
were fasted and blood glucose and serum insulin were measured as previously 
described. 2-way ANOVA on the effects of genotype and diet on fasting blood glucose 
revealed significant main effects of diet (F(1,35) = 14.44, p = 0.0014) and genotype (F(1,35) 
= 35.67, p < 0.0001), with a statistically significant interaction between diet and 
genotype (F(1,35) = 6.72, p = 0.0239; Fig 3.3-A). Post-hoc tests showed that HFD 
increased glucose levels in WT-FL mice but not in macNOX2KO mice, while planned 
comparisons revealed that glucose levels in HFD-fed WT-FL mice were significantly 
higher than levels in HFD-fed macNOX2KO mice (Fig 3.3-A). Conversely, 2-way 
ANOVA on the effects of genotype and diet on fasting insulin revealed a significant  
 75 
 
Figure 3.3: Effects of HFD on metabolic parameters in WT-FL and macNOX2KO mice. 
At the end of the 16-wk feeding trial mice were fasted and blood glucose, serum insulin, 
and serum lipids were measured. Significant effects of diet are indicated with “*” (*p < 
0.05, **p < 0.01, and ***p < 0.001), while significant effects of genotype are indicated 
with “#” (#p < 0.05, ##p < 0.01, and ###p < 0.001). Figure 3.3-A: Fasting blood glucose 
levels. Significant (**p < 0.01) increase in fasting blood glucose in WT-FL mice on HFD 
vs. CD. Significant (#p < 0.05) decrease in fasting blood glucose in macNOX2KO mice 
vs. WT-FL mice on HFD. Figure 3.3-B: Fasting insulin levels. Significant (***p < 0.001 
and *p < 0.05, respectively) increases in fasting insulin in WT-FL mice on HFD and 
macNOX2KO mice on HFD. Significant (###p < 0.001) decrease in fasting insulin in 
macNOX2KO mice vs. WT-FL mice on HFD. Figure 3.3-C: HDL cholesterol levels. 
Significantly (***p < 0.001) lower HDL in WT-FL mice on HFD vs. CD. Significant (#p < 
0.05) increase in HDL in macNOX2KO mice vs. WT-FL on HFD. Figure 3.3-D: 
Triglyceride levels. Significant (**p < 0.01) increase in triglycerides in WT-FL on HFD vs. 
CD. Significantly (###p < 0.001) lower triglycerides in macNOX2KO mice vs. WT-FL on 
HFD. Figure 3.3-E: Total cholesterol levels measured in WT-FL and macNOX2KO mice 
after administration of HFD or CD. Significant (***p < 0.001 and **p < 0.01, respectively) 
increases in total cholesterol in WT-FL mice on HFD and macNOX2KO on HFD. 
Significantly (#p < 0.05) lower total cholesterol in macNOX2KO mice vs. WT-FL mice on 
CD. Significantly (###p < 0.001) lower total cholesterol in macNOX2KO mice vs. WT-FL 
mice on HFD. Figure 3.3-F: LDL cholesterol levels. Significant (*p < 0.05) increase in 
LDL in WT-FL mice on HFD. Significantly (##p < 0.01) lower LDL in macNOX2KO mice 
vs. WT-FL mice on HFD.  
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 effect of diet (F(1,35) = 14.44, p = 0.0014), but no effect of genotype and no interaction 
(Fig 3.3-B). Studies next assessed a panel of bioactive serum lipids in WT-FL and 
macNOX2KO mice, measured under fasted conditions as described in Materials and 
Methods. Data showed a significant effect of diet (F(1,34) = 44.49, p < 0.0001) on total 
cholesterol, but no effect of genotype, no interaction, and no significant differences 
between WT-FL and macNOX2KO mice (Fig 3.3-C). Likewise, there were significant 
effects of diet on LDL cholesterol (F(1,34) = 26.17, p = 0.0013) and on HDL cholesterol 
(F(1,34) = 30.13, p = 0.0004), but no effects of genotype and no interactions. Additionally, 
posthoc tests showed that HFD increased LDL and HDL cholesterol species in WT-FL, 
but not macNOX2KO mice (Fig 3.3-D & Fig 3.3-E). Finally, there were no differences in 
levels of fasting triglycerides or NEFA in either WT-FL or macNOX2KO mice given 
either CD or HFD (Fig 3.3-F).   
Effects of HFD on cognitive function and brain injury in WT-FL and macNOX2KO mice 
 We have previously shown that HFD administration causes significant 
impairments in memory performance in mice (Pepping et al., 2013; Freeman et al., 
2013). To determine if conditional deletion of NOX2 from macrophages can preserve 
cognitive function, CD- and HFD-fed WT-FL and macNOX2KO mice were evaluated 
using the fear conditioning assay as described in Methods. No significant differences in 
behavioral responses across groups were observed on day 2 (data not shown), 
indicating that all mice retained the basic memory of the conditioned context. However, 
differences in freezing behavior were observed on the third day of the fear conditioning 
test, when the ‘‘tone test” conducted in an entirely novel environment provides a 
measure of associative learning.  
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Specifically, freezing behavior in response to the tone was more in HFD-fed 
macNOX2KO mice as compared to HFD-fed WT-FL mice (Fig 3.4), suggesting 
improved memory of the tone cue. 
3.4 Discussion 
 Data in this manuscript strongly support NOX2-based signaling in macrophages 
as being a key contributor to the detrimental effects of diet-induced obesity. In this study 
specifically, data show that, while both WT-FL and macNOX2KO mice became obese 
following HFD administration, macNOX2KO mice had attenuated adipose pathology 
and preserved adipose function. Additionally, glucose tolerance was normalized in 
macNOX2KO mice compared to WT-FL mice following HFD, and HFD-induced brain 
injury was prevented in macNOX2KO mice. Thus, the macNOX2KO mice were 
protected from the HFD effects.  Overall, these data are consistent with previous studies 
demonstrating increased NADPH oxidase activity/expression in models of obesity 
(Bruce-Keller et al., 2010; Chinen et al., 2007; Zhang et al., 2005) and are also in 
agreement with the growing body of literature describing the sensitivity of the brain to 
obesity-induced metabolic dysfunction (reviewed in (Bruce-Keller et al., 2009; Middleton 
and Yaffe, 2009)). Moreover, these data significantly enhance the findings of previous 
studies with the demonstration that NOX2 is a specific and powerful mediator of 
pathogenic effects of diet-induced obesity that extend from adipocytes to brain cells. 
These data indicate that NOX2-signaling in visceral adipose macrophages precipitates 
loss of adipocyte function and the development of ER stress within adipose tissues, 
triggering pathways that ultimately result in loss of metabolic and neurologic function. 
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Figure 3.4: Effects of HFD on cognitive function in WT-FL mice and macNOX2KO mice. 
Mice were evaluated using the fear conditioning assay as described in Materials and 
Methods. Significantly (*p < 0.05, *p < 0.05, **p <0.01) more freezing to tone at 6 min, 7 
min, and 8 min in NOX2KO mice vs. WT mice on HFD.  
 
Collectively, these data raise the possibility that macrophage-specific NOX2-based 
therapies could be used clinically to preserve both metabolic and neurologic function in 
the context of obesity.   
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Chapter 4. Conclusions 
 
 The intent of our first study was to determine if deletion of NOX2 does indeed 
provide protection from the deleterious effects of high-fat diet-induced adiposopathy.  
After establishing this to be true, we set out to develop a cre-lox knockout mouse model 
with deletion of NOX2 restricted to macrophages.  After completing this, the intent of our 
second study was to determine if macrophage-specific NOX2 deletion also provides 
protection while also preserving the beneficial roles of NOX2, namely in cognitive 
functioning.  Both studies that were conducted resulted in significant developments in 
the investigation of NOX2 as a key contributor to high-fat diet-induced adiposopathy and 
neurologic impairment.  The first study looked at the implications of a whole-body 
deletion of NOX2, as well as where the majority of NOX2 was expressed.  It was 
important for us to focus our studies on looking at NOX2 in macrophages, because prior 
studies have suggested that NOX2 is localized to macrophages and not adipocytes 
(Han et al., 2012, Mahadev et al., 2004; Schroder et al., 2009) 
 A limitation of the first study that may have played a minor role in affecting the 
results was that we were unable to house the NOX2KO mice and the WT mice in the 
same room under the same conditions.  This was due to the fact that the NOX2KO mice 
have increased susceptibility to pathogens (Pollock, 1995), and based on our pilot 
study, it was discovered that these mice can develop sterile granulomas in response to 
being housed in a conventional room.  Thus, we had to house the NOX2KO mice under 
sterile conditions. 
 In the first study, the results provided evidence that NOX2KO mice on a high-fat 
diet have less visceral adipose tissue pathology and improved glucose tolerance.  
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Additionally, these mice have less brain injury.  Numerous studies have shown that 
NADPH oxidase plays a role in the pathogenesis of neurodegenerative diseases (Block, 
2008; Lambeth, 2007; Shimohama et al., 2000).  NOX2 does play a role in brain 
inflammation, but it also plays a role in physiologic cognitive and memory functioning as 
well (Kishida and Klann, 2007; Kishida et al., 2005; Tejada-Simon et al., 2005).  In light 
of this, and because the whole-body NOX2KO mice are cognitively impaired (Kishida et 
al., 2006; Pao et al., 2004)., we were unable to assess cognitive functioning via 
behavioral testing, since the mice would be unable to perform the tests appropriately 
due to cognitive deficits.  A future area of investigation would be to use cre-lox knockout 
mice to target certain areas and cells in the brain so as to inhibit pathological effects but 
preserve physiologic effects. 
 Lack of effective antibodies for the detection of NOX2 expression was another 
limitation of these studies.  If antibodies could be developed that are specific for NOX2, 
this would greatly aid in validating NOX2 expression.  Through genetic testing and PCR, 
we confirmed that NOX2 was deleted in the appropriate mice, but additional 
confirmation through the use of specific antibodies would be helpful.  This would also 
allow for improved investigation as to where NOX2 is being expressed specifically.   
 Because adiposopathy and not obesity is the driving factor in development of 
metabolic impairments, therapies that look specifically at alleviating adiposopathy and 
not necessarily obesity should be investigated.  The challenge of finding a treatment 
modality that effectively alleviates obesity (Padwal et al., 2004) suggests that focusing 
on protecting the adipose tissue by targeting NOX2 may be more effective.   
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Our data suggest that therapies could be developed to target NOX2 in order to preserve 
metabolic and neurologic function in the context of obesity.   
 Additional studies should be conducted to determine if inhibition of NOX2 has the 
potential to be therapeutic on a pharmacologic level.  One way this could be done is 
through the use of a glucan-based encapsulation system to target visceral adipose 
macrophages.  This encapsulation system utilizes shells extracted from Saccharomyces 
cerevisiae (baker’s yeast) to deliver siRNA (Aouadi et al., 2009; Soto and Ostroff, 2008).  
Specifically, NOX2 siRNA could be loaded into these beta glucan microspheres and 
then given via intraperitoneal injection to wild type mice on a high fat diet.  The expected 
result would be that NOX2 expression will be decreased in these mice.  Exploring this 
option and others, could result in viable therapeutic options to treat adiposopathy. 
4.1 Bibliography 
Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, Ostroff GR, Czech 
 MP. 2009. Orally delivered siRNA targeting macrophage Map4k4 suppresses 
 systemic inflammation. Nature 458:1180-1184. 
 
Block ML. 2008. NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC 
 Neuroscience 9 Suppl 2:S8. 
 
Han CY, Umemoto T, Omer M, Den Hartigh LJ, Chiba T, LeBoeuf R, Buller CL, Sweet 
 IR, Pennathur S, Abel ED, Chait A. 2012. NADPH oxidase-derived reactive 
 oxygen species increases expression of monocyte chemotactic factor genes in 
 cultured adipocytes. Journal of Biological Chemistry 287:10379-10393. 
 
Kishida KT, Pao M, Holland SM, Klann E. 2005. NADPH oxidase is required for NMDA 
 receptor-dependent activation of ERK in hippocampal area CA1. Journal of 
 Neurochemistry 94:299-306. 
 
Kishida KT, Hoeffer CA, Hu D, Pao M, Holland SM, Klann E. 2006. Synaptic 
 plasticity deficits and mild memory impairments in mouse models of chronic 
 granulomatous disease. Molecular and Cellular Biology 26:5908-5920. 
 
Kishida KT, Klann E. 2007. Sources and targets of reactive oxygen species in 
 synaptic plasticity and memory. Antioxidants and Redox Signaling 9:233-244. 
 86 
Lambeth JD. 2007. Nox enzymes, ROS, and chronic disease: an example of 
 antagonistic pleiotropy. Free Radical Biology and Medicine 43:332-347. 
 
Mahadev K, Motoshima H, Wu X, Ruddy JM, Arnold RS, Cheng G, Lambeth JD, 
 Goldstein BJ. 2004. The NAD(P)H oxidase homolog Nox4 modulates 
 insulin-stimulated generation of H2O2 and plays an integral role in insulin signal 
 transduction. Molecular and Cellular Biology 24:1844-1854. 
 
Padwal R, Li SK, Lau DC. 2004. Long-term pharmacotherapy for obesity and 
 overweight. Cochrane Database of Systemic Reviews 3:CD004094. 
 
Pao M, Wiggs EA, Anastacio MM, Hyun J, DeCarlo ES, Miller JT, Anderson VL, 
 Malech HL, Gallin JI, Holland SM. 2004. Cognitive function in patients with 
 chronic granulomatous disease: a preliminary report. Psychosomatics 
 45:230-234. 
 
Pollack JD, Williams DA, Gifford MAC, Li LL, Du X, Fisherman J, Orkin SH, 
 Doerschuk, Dinauer MC. 1995. Mouse model of X-linked chronic granulomatous 
 disease, an inherited defect in phagocyte superoxide production. Nature 
 Genetics 9:202-209. 
 
Schröder K, Wandzioch K, Helmcke I, Brandes RP. 2009. Nox4 acts as a switch 
 between differentiation and proliferation in preadipocytes. Arteriosclerosis,  
 Thrombosis, and Vascular Biology 29:239-245. 
 
Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, 
 Hayakawa T, Nunomura A, Chiba S, Perry G, Smith MA, Fujimoto S. 2000. 
 Activation of NADPH oxidase in Alzheimer's disease brains. Biochemical 
 Biophysical Research Communications 273:5-9. 
 
Soto ER and Ostroff GR. 2008. Characterization of multilayered nanoparticles 
 encapsulated in yeast cell wall particles for DNA delivery. Bioconjugate 
 Chemistry 19:840-848. 
 
Tejada-Simon MV, Serrano F, Villasana LE, Kanterewicz BI, Wu GY, Quinn MT, Klann 
 E. 2005. Synaptic localization of a functional NADPH oxidase in the mouse 
 hippocampus. Molecular and Cellular Neuroscience 29:97-106. 
 
 
 
 
 
 
 
 
 
 87 
Appendix Permission to Publish 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 88 
Vita 
 
 Jennifer Kathleen Pepping was born in Olympia Fields, Illinois.  She graduated 
from Geneva High School in 2003.  After graduation, she attended University of Illinois 
Urbana-Champaign where she graduated in 2007 with a Bachelor of Science in animal 
sciences.  After undergraduate school, she continued her studies at the University of 
Illinois Urbana-Champaign, where she attended veterinary school at the College of 
Veterinary Medicine.  She graduated from veterinary school in 2011.  Immediately 
following graduation, Jennifer began a residency program in Laboratory Animal 
Medicine within the Division of Laboratory Animal Medicine (DLAM) at Louisiana State 
University School of Veterinary Medicine.  During the residency, she also began her 
graduate studies in the Department of Pathobiological Sciences.  She completed her 
residency program in 2014.  Following the residency program, she continued to work on 
her graduate studies and is currently a candidate for the Master of Science degree in 
Veterinary Medical Sciences under the direction of Dr. Rhett W. Stout and Dr. Annadora 
Bruce-Keller. 
 
 
 
 
 
 
 
 
